

QL

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 14/00, 14/435, C12N 5/16, 15/12, 15/63, G01N 33/53, 33/566		A1	(11) International Publication Number: WO 00/12546
			(43) International Publication Date: 9 March 2000 (09.03.00)
(21) International Application Number: PCT/US99/19902 (22) International Filing Date: 31 August 1999 (31.08.99) (30) Priority Data: 60/098,413 31 August 1998 (31.08.98) US (71) Applicant (for all designated States except US): THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK [US/US]; P.O. Box 9, Albany, NY 12201-0009 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): McKINNON, David [AU/US]; 27 Braemer Road, East Setauket, NY 11733 (US). DIXON, Jane, E. [AU/US]; 27 Braemer Road, East Setauket, NY 11733 (US). (74) Agent: LIN, Maria, C., H.; Morgan & Finnegan LLP, 345 Park Avenue, New York, NY 10154 (US).		(81) Designated States: AT, AU, BR, CA, CN, HU, IL, JP, KR, MX, NO, NZ, PL, RO, SG, US, ZA, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: MAMMALIAN <i>elk</i> POTASSIUM CHANNEL GENES (57) Abstract The present invention is directed to the isolation, cloning and sequencing of mammalian <i>elk1</i> , <i>elk2</i> , and <i>EAG2</i> K channel genes. The amino acid sequences of the expressed proteins are also provided. Information on the distribution of the gene and their expression products in various relevant nervous system tissue is also provided. The gene and protein sequences and the distribution pattern information is helpful in the research and development of pharmaceuticals with specific action on the different K channels.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakistan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

MAMMALIAN *elk* POTASSIUM CHANNEL GENESFIELD OF THE INVENTION

The present invention relates to the isolation, cloning and sequencing of genes and the encoded proteins for voltage-gated potassium channels (K channels). More particularly, the invention is directed to the isolation, cloning and sequencing of *eag* and *eag-like-K+* channel genes (*elk*).

The availability of these genes provide the tools for further reasearch into the physiobiological characteristics of the various genes and proteins for K channels; the development of medicines which are effective for treating the specific disease conditions arising from mutations or defects in the specific K channels and the screening of drugs to ensure that the *elk* potassium channels will not be blocked. The availability of the *elk* gene/*elk* protein ensures that drugs screened for the treatment of other diseases will not affect the physiological functions controlled by the *eag* and *elk* potassium channel gene.

BACKGROUND OF THE INVENTION

Potassium channels (K channels) play a major role in a wide range of cellular functions, including electrical excitability and synaptic plasticity in neurons. K channels are involved in determining and stabilizing the resting membrane potential, the re-polarization of action potentials, control of firing patterns and modulation of neurotransmitter release of nerve cells. Some of the functions controlled are basic, such as the setting of the resting potential; and some of the functions are very specific, such as defining the interval between spikes of endogenously beating cells. These

functions are involved in a number of physiological processes, including regulation of heartbeat, dilation of arteries, release of insulin, excitability of nerve cells, and regulation of renal electrolyte transport. Potassium channels are thus found in a wide variety of animal cells such as nervous, muscular, glandular, immune, reproductive, and epithelial tissue. These channels allow the flow of potassium ions in and/or out of the cell under certain conditions. For example, the outward flow of potassium ions upon opening of these channels makes the interior of the cell more negative, counteracting de-polarizing voltages applied to the cell. These channels are regulated, e.g., by calcium sensitivity, voltage-gating, second messengers, extracellular ligands, and ATP-sensitivity. It is important for the potassium channels to be operating properly to maintain healthy functions in the body. It is, therefore important that medicines for the treatment of diseases unrelated to the function of the ion channels do not adversely affect the proper function of these channels.

It is known that a variety of genes encode the proteins of the K channels with diverse electrophysiological and pharmacological properties. H. Terlau et al., Pflughers Arch., (1996) 432:301-312. The research is ongoing to determine the number of the genes involved and the characteristics and functions of the proteins which the genes encode.

Based on recent molecular cloning studies, a hierarchical classification scheme has been developed. Sodium, calcium and potassium channels belong to a 'superfamily' of ion channels.

Structurally, K channels can also be grouped into

three main classes: six-transmembrane (6TM), four-transmembrane (4TM) and two-transmembrane (2TM) subunits. The 6TM superfamily may be further divided into six families, among which are the voltage-gated, KQT-like, EAG-like, Slo-like, cyclic nucleotide-gated and "SK" channels. Each of the families may be further subdivided into "subfamilies". For example, in the voltage-gated family, there are four subfamilies: Shaker, Shab, Shaw and Shal, corresponding to Kv1, Kv2, Kv3 and Kv4, respectively. Between subfamilies of the 6TM family, the observed amino acid sequence homology is about 40%. A higher degree of homology, 50%-70%, is shared among members of a single subfamily of the 6TM family. This is true intra or inter species. Whereas, in the 2TM and 4TM families, much less conservation is observed across species. A schematic of the classification scheme is shown in Fig.1. A. Wei et al., supra.

Potassium channels are typically formed by four alpha subunits, and can be homomeric (made of identical alpha subunits) or heteromeric (made of two or more distinct types of alpha subunits). In addition, potassium channels made from Kv, KQT and Slo subunits have often been found to contain additional, structurally distinct auxiliary, or beta, subunits. These subunits do not form potassium channels themselves, but instead they act as auxiliary subunits to modify the functional properties of channels formed by alpha subunits. For example, the Kv beta subunits are cytoplasmic and are known to increase the surface expression of Kv channels and/or modify inactivation kinetics of the channel (Heinemann et al. J. Physiol 493:625-633 (1996); Shi et al., Neuron 16(4):843-852 (1996)). In another example, the KQT family beta subunit, minK, primarily changes activation kinetics (Sanguinetti et al., Nature 384:80-83 (1996)).

Voltage-gated K channels are encoded by two groups: the extended Shaker family including the Ca^{2+} -activated SK and BK channels and those ion channels with a cyclic nucleotide-binding domain. The latter include the cyclic nucleotide-gated channels, the plant inward-rectifying channels and the ether-a-go-go (EAG) channels. H. Terlau et al., J. Physiol., (1997) 502.3:537-543. The eag-like family comprise three related voltage-gated K channel genes. The first of the family, the eag gene, was initially identified in *Drosophila*. J. Warmke et al., Science (1991) 252:1560-1562. Two related *Drosophila* genes were subsequently described: the eag-related-gene (erg) and the eag-like- K^+ channel gene (elk). Warmke and Ganetzky, PNAS, USA (1994) 91: 3438-3442. Mammalian homologues of the eag genes have been identified and the potassium channels that they encode have been expressed and characterized. Warmke and Ganetzky (1994), supra; J. Ludwig et al., EMBO J. (1994) 13:4451-4458; G.A. Robertson et al., Neuropharmacol. (1996) 35:841-850; and W. Shi et al., J Neurosci. (1997) 17:9423-9432.

Up to late 1997, only a single representative of the erg family, human erg (Herg) was found. There is considerable interest in the erg gene because mutations were shown to underlie one form of a human genetic disease known as long QT (LQT) syndrome, which gives rise to cardiac arrhythmia and an increase incidence of sudden death.

In *Xenopus* oocytes, Herg forms voltage-sensitive K channels with a distinctive inactivation mechanism that attenuates efflux of K^+ during depolarization (Sanguinetti et al., Cell (1995) 81, 299-307. The erg channels most closely resemble those of native cardiac I_{Kr} channels. Through tissue distribution studies, it was found that the Herg gene is expressed abundantly in the nervous system and heart muscle.

Up to the present three members of the mammalian *erg* family have been cloned and sequenced by the inventors and reported in W. Shi et al, J. Neurosci. (1997) 17:9423-9432.

5 The rat *eagl* has also been identified, cloned and sequenced. No other *eag* gene has been identified, or cloned. To date, no mammalian homologue of the *Drosophila elk* gene has been described, nor have the biophysical properties of any *elk* channel been characterized.

OBJECTIVES OF THE INVENTION

10 It is an objective of this invention to isolate, clone, and sequence further *eag* and *elk* genes and to use the nucleic acid sequences obtained to deduce the amino acid sequence of the proteins encoded by further *eag* and *elk* genes.

15 It is another objective of this invention to isolate, clone, and sequence other genes in the *eag*-like family and to use the nucleic acid sequences obtained to deduce the sequence of the protein encoded by other *eag*-like genes.

It is another objective to determine the biophysical and pharmacological properties of the channels encoded.

20 It is a further objective to determine the distribution pattern of the mRNA of all known *eag*-like genes in sympathetic ganglia and sciatic nerve.

SUMMARY OF THE INVENTION

25 Three new members of the mammalian *eag*-like gene family are identified using rat sympathetic ganglia tissue.

The *elk1* gene has been isolated, cloned and the complete coding sequence (SEQ ID NO:1, Fig. 3) identified. The gene has been expressed in *Xenopus* oocytes and the deduced amino acid sequence (SEQ ID NO:2, Fig 2) of the *elk1* protein

was also determined. The biophysical and pharmacological properties of the *elk1* encoded channel has also been analyzed. The *elk2* gene was also isolated, cloned and sequenced (SEQ ID NO:13) and the amino acid sequence (SEQ ID NO:3) of the protein deduced.

Further, another member of the *eag* family, the *eag2* gene was isolated, cloned and sequenced (SEQ ID NO:14) and its deduced amino acid sequence (SEQ ID NO:4) determined.

In addition, the mRNA distribution pattern in rat sympathetic ganglia and sciatic nerve of all known *eag* genes was obtained using three sympathetic ganglia: one paravertebral ganglia, the superior cervical ganglia (SCG); and two prevertebral ganglia, the coeliac ganglia (CG) and the superior mesenteric ganglia (SMG).

The results indicate that The *elk1* gene is expressed in both prevertebral and paravertebral ganglia at approximately equal levels. In contrast, the *elk2* gene is not expressed at detectable levels in sympathetic ganglia, although it is robustly expressed in the brain. Both *eag* genes are expressed in sympathetic ganglia. The *eag1* gene is expressed at high levels in all three sympathetic ganglia. The *eag2* gene is only expressed at significant levels in the prevertebral ganglia, the CG and SMG.

In addition to neurons, sympathetic ganglia also contain glial cells (known as satellite cells and developmentally related to Schwann cells). To determine whether gene expression in ganglia could be due to expression in glial cells, *EAG* gene expression was examined in sciatic nerve, which contains a relatively pure population of Schwann cells. Two of the seven *EAG* genes tested, *elk1* and *erg1*, are expressed in sciatic nerve (Fig. 4B).

A summary of *EAG* gene expression in sympathetic ganglia and sciatic nerve is shown in Table 1. At least six *EAG* genes are expressed in the sympathetic ganglia and all seven *EAG* genes are expressed in at least one neuronal tissue.

5 Two genes, *eag2* and *erg2*, are differentially expressed in sympathetic ganglia. Both genes are expressed at higher levels in prevertebral ganglia than paravertebral ganglia. The housekeeping gene cyclophilin was expressed at significantly lower levels in sciatic nerve RNA than in
10 ganglia or brain RNA (Fig. 4B). It is possible, therefore, that mRNA levels, as a fraction of total RNA, are significantly lower in sciatic nerve than in ganglia or brain. For this reason, the relative level of *elk1* and *erg1* expression in sciatic nerve described in Table 1 may be an
15 underestimate in comparisons between sciatic nerve and ganglia or brain.

Utilizing the information obtained from rat *elk1*, *elk2* and *eag2* the corresponding human genes can be obtained and the protein encoded thereby expressed.

20 The present invention thus provides isolated nucleotides from rat and human tissue encoding a polypeptide forming a potassium channel. The polypeptide is selected from the group consisting of *elk1*, *elk2* and *eag2*. The *elk1* polypeptide forms a channel having the characteristic of a
25 slowly activated outward rectifier, with an activation constant of about 100 ms at 0 mV with a threshold of -40 mV. The *eag*-like K channels also exhibits no apparent inactivation during de-polarizing voltage steps of up to several seconds.

The *elk1* channel is characterized by having a
30 activation time constant of 676 ± 37 ms at 0 mV with a threshold of activation at -40 mV and a deactivation rate of

111 \pm 7 ms at -50 mV at about pH 7. Based on our observations, the activation/deactivation rate for elk1 is dependent on the pH of the solvent. However, for elk2 and eag2, the activation/deactivation rate is not as pH dependent.

5 The polypeptide elk1 has a molecular weight of between 100 kDa to 150 kDa, about 123 kDa. The polypeptides elk2 and eag2 have a molecular weight similar to that of elk1 of between 100 kDa to 150 kDa.

10 The nucleic acids encoding elk1, elk2, or eag2 are amplified by primers that selectively hybridize under stringent conditions to sequences that hybridize to the primers. For elk1, the primers are SEQ ID NO:5 and SEQ ID NO:6; for elk2, the primers are SEQ ID NOS:9 and 10 and for eag2, the primers are SEQ ID NOS:5 and 6. To obtain the
15 equivalent human elk1, elk2 or eag2, the primers may be selected by a comparison of the rat elk1, elk2 or eag2 nucleic acid sequences respectively with the human EST sequences listed in Genbank using the BLAST or PILEUP programs. Sequences from the list of human EST which shows the highest
20 homology with a region of each of the rat sequences for elk1, elk2 or eag2 are obtained. From the EST sequences obtained, nucleotides of between 17 to 25 base pairs with at least 90% homology between the rat and human sequences are selected for use as primers.

25 In another aspect, the present invention provides an antibody that selectively binds to the polypeptide elk1, elk2 or eag2 described above.

 The present invention further provides expression factors comprising the nucleic acid sequences encoding elk1,
30 elk2 or eag2.

The present invention further provides host cells transfected with the expression vectors described above.

In another aspect, the present invention provides a method of drug screening to ensure that the compounds
5 identified for use as drugs for other diseases do not have a deleterious effect on the function of the elk1, elk2 or eag2 potassium channels. The method comprises the steps of: (a) contacting the compound with a eukaryotic host cell or cell membrane in which has been expressed a polypeptide comprising
10 an alpha subunit of a potassium channel selected from the group consisting of elk1, elk2 and eag2, the potassium channel having the characteristic of a slowly activated outward rectifier; and (b) determining the functional effect of the compound upon the cell or cell membrane expressing the
15 potassium channel. One example of the cell or cell membrane expressing the potassium channels are *Xenopus* oocytes or the membranes thereof.

In one embodiment, the functional effect is determined by measuring changes in current or voltage. In another
20 embodiment, the polypeptide monomer polypeptide is recombinant. In another embodiment, the potassium channel is homomeric or heteromeric.

In another embodiment, the present invention provides a method of detecting the presence of elk1, elk2 or eag2 in
25 mammalian tissue, the method comprising the steps of: (i) isolating a biological sample; (ii) contacting the biological sample with a reagent that selectively associates with elk1, elk2 or eag2; and, (iii) detecting the level of reagent that selectively associates with the sample. The reagent is
30 selected from the group consisting of: antibodies specific for elk1, elk2 or eag2, oligonucleotide primers specific for elk1,

elk2 or *eag2*, and for *elk1*, *elk2* or *eag2* nucleic acid probes. The mammalian tissue may be from rat or human.

The present invention also provides, in a computer system, a method of screening for mutations of *elk1*, *elk2* or *eag2* genes, the method comprising the steps of: (i) entering
5 into the computer system a first nucleic acid sequence encoding an slowly activated outward rectifier potassium channel protein having a nucleic acid sequence of SEQ ID No:1, or comprising a nucleic acid sequence SEQ ID No:13 or SEQ ID
10 No:14; and conservatively modified versions thereof; (ii) comparing the first nucleic acid sequence with a second nucleic acid sequence having substantial identity to the first nucleic acid sequence; and (iii) identifying nucleotide differences between the first and second nucleic acid
15 sequences.

The second nucleic acid sequence may be associated with a disease state. Or, the computer readable substrate comprises the first and the second nucleic acid sequences.

The present invention further provides, in a computer
20 system, a method for identifying a three-dimensional structure of *elk1*, *elk2* or *EAG2* polypeptides, the method comprising the steps of: (i) entering into the computer system an amino acid sequence of at least 10 amino acids of *elk1*, *elk2* or *eag2* or at least 30 nucleotides of a gene encoding the *elk1*, *elk2* or
25 *eag2* polypeptide, the polypeptide having an amino acid sequence of SEQ ID No: 2, or comprising the partial amino acid sequence SEQ ID No:3 or SEQ ID No:4 and conservatively modified versions thereof; and (ii) generating a three-dimensional structure of the polypeptide encoded by the amino
30 acid sequence.

In one embodiment, the amino acid sequence is a

primary structure and wherein said generating step includes the steps of: (i) forming a secondary structure from said primary structure using energy terms determined by the primary structure; and (ii) forming a tertiary structure from said secondary structure using energy terms determined by said secondary structure. In another embodiment, the generating step includes the step of forming a quaternary structure from said tertiary structure using anisotropic terms determined by the tertiary structure. In another embodiment, the methods further comprises the step of identifying regions of the three-dimensional structure of the protein that bind to ligands and using the regions to identify ligands that bind to the protein. In another embodiment, a computer readable substrate comprises the three dimensional structure of the polypeptide monomer.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a schematic representation of the classification of the K channel genes.

Fig. 2 is an alignment of the *elk1*, *erg1* and *eag1* deduced amino acid sequences. Identical residues are double underlined and similar residues are single underlined. The six hydrophobic domains (S1-6), and the pore (P) and the putative cyclic nucleotide binding domain (CNBD) are overlined.

Fig. 3 is the cDNA sequence of the *elk1* gene (SEQ ID NO.1).

Figs. 4A-4H show the electrophysiological characteristics of the rat *elk1* expressed in *Xenopus* oocytes.

Fig. 4A shows the voltage-clamp recordings of *elk1* currents with voltage steps over the range of -60 to +50 mV

from a holding potential of -70 mV. Tail currents were recorded at -50 mV.

Fig. 4B show the normalized conductance-voltage curve of the elk1 channel. Conductance of the channel was calculated as the current measured at the end of a 2 second depolarizing step divided by the driving force ($E_K = -75$ mV). Data points are averages from 7 oocytes and were fitted with the equation:

$$G/G_{\max} = 1 / (1 + \exp((V - V_n) / k_n))$$

where V_n , the midpoint for activation, was 9.3 ± 0.4 mV, and k_n , the slope factor, was -13.1 ± 0.3 mV. Error bars are s.e.m. and are not as large as the graph symbols.

Fig. 4C depicts the activation of elk1 and rat eag1 channels from different holding potentials. Holding potentials were varied over the range -120 mV to -40 mV in 20 mV increments. Test potential was 0 mV. The difference in time scale for the two types of channel is to be noted.

Fig. 4D shows the deactivation of elk1 channel tail currents. Currents were activated by a 2500 ms step to +10 mV followed by steps to potentials over the range -90 to -30 mV in 10 mV increments. Time constants for deactivation are indicated next to the appropriate trace. The trace at -70 mV is not shown due to the small amplitude of the tail current.

Fig. 4E shows the activation of the elk1 channel in control perfusion solution (pH = 7.7, left) and in perfusion solution with pH lowered to 6.6 (right). Recordings show current responses to voltage steps from a holding potential of -70 mV. Test potentials are indicated next to selected current traces.

Fig. 4F depicts conductance-voltage curves in perfusion solutions with various pH values. Data points were

fitted with the equation:

$$G = G_{\max} / (1 + \exp((V - V_n) / k_n))$$

where the midpoint for activation $V_n = 9.6, 8.6, 15.7, 25.2,$
and 9.0 mV, the slope factor $k_n = -13.8, -13.7, -12.5, -12.3,$
5 -13.4 mV and the maximum conductance $G_{\max} = 26.8, 26.3, 24.1,$
 $21.8, 25.8$ μ S for pH = $7.7, 8.6, 7.1, 6.6,$ and wash (7.7)
respectively.

Fig. 4G shows that E4031 does not block the *elk1* channel. Voltage-clamp protocol is the same as in Fig. 4A.

10 Fig. 4H shows the *elk1* channel is blocked by 1 mM Ba^{2+} . Voltage-clamp protocol is the same as in Fig. 4A.

Fig. 5A and 5B show autoradiographs of RNase protection assays showing *EAG* potassium channel mRNA expression in sympathetic ganglia, brain and sciatic nerve
15 determined by RNase protection analysis.

Fig. 5A shows samples tested: superior cervical ganglia (SCG), coeliac ganglia (CG), superior mesenteric ganglia (SMG) and brain. For the sympathetic ganglia, the sample always contained 5 μ g of total RNA. A variable amount
20 of total RNA was included in the brain samples as noted. In gel a) *elk1* mRNA was expressed in all three sympathetic ganglia. The brain sample contained 5 μ g of total RNA. In gel b) *elk2* mRNA was not expressed in sympathetic ganglia but was moderately abundant in brain. The brain sample contained 2.5
25 μ g of total RNA. In gel c) *eag1* mRNA was expressed at equal levels in all three ganglia and was also expressed in brain. The brain sample contained 14 μ g of total RNA. In gel d) *eag2* mRNA was barely detectable in the SCG but was expressed in the two prevertebral ganglia, the CG and SMG, as well as in brain.
30 The brain sample contained 14 μ g of total RNA.

Fig. 5B shows *elk1* and *erg1* mRNA expression in sciatic nerve (SN). Superior cervical ganglia (SCG) RNA served as a positive control. All samples contained 5 µg of total RNA.

The cyclophilin gene (*cyc*) was used as an internal positive control in all experiments to check for sample loss and equal loading.

LIST OF REFERENCES

1. Alberts et al., Molecular Biology of the Cell 3rd ed., (1994)
- 10 2. Batzer et al., Nucleic Acid Res. (1991) 19:5081.
3. Belluzzi, O. & Sacchi, O., Prog. Biophys. Molec. Biol. (1991) 55:1-30.
4. Altschul et al., J. Mol. Biol. (1990) 215:403-410.
5. Brown, D. A., Ion Channels, ed. Narahashi, T., pp. 55-94.
- 15 Plenum, New York (1988).
6. Brown, D. A. & Adams, P. R., Nature (1980) 283:673-676.
7. Brown, D. A., Adams, P. R. & Constanti, A., J. Auton. Nerv. Syst. (1982) 6:23-35.
8. Cantor & Schimmel, Biophysical Chemistry, Part I: The
- 20 Conformation of Biological Macromolecules, (1980)
9. Chen, M. L., Hoshi, T. & Wu, C. F. Neuron (1996) 17:35-542.
10. Creighton, Proteins (1984)
11. Devereaux et al., Nucleic Acids Res., (1984) 12:387-395.
- 25 12. Dixon, J. E. & McKinnon, D., Eur. J. Neurosci. (1996) 8:83-191.
13. Feng & Doolittle, J. Mol. Evol. (1987) 35:35 1-360.
14. Frohman, M. A., PCR Meth. Appl. (1994) 4:40-S58.
15. Ganetzky, B. & Wu, C. F., J. Neurogenetics (1983) 1:17-30 28.
16. Harlow & Lane, Antibodies, A Laboratory Manual (1988)

17. Heinemann et al. J. Physiol (1996) 493:625-633.
18. Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA (1989) 89:10915.
19. Higgins & Sharp, CABIOS (1989) 5:151-153.
- 5 20. Karlin & Altschul, Proc. Natl. Acad. Sci. USA (1993) 90:5873-5787.
21. Ludwig, J., Terlau, H., Wunder, F., Bruggemann, A., Pardo, L. A., Marquardt, A., Stuhmer, W. & Pongs, O., EMBO J. (1994) 13:451-4458.
- 10 22. McCafferty et al., Nature (1990) 348:552-554.
23. Meyer, R. & Heinemann, S. H., J. Physiol. (1998) 508:9-56.
24. Needleman & Wunsch, J. Mol. Biol. (1970) 48:443.
25. Obtsuka et al., J. Biol. Chem. (1985) 260:260S-2608.
- 15 26. Pearson & Lipman, Proc. Natl. Acad. Sci. USA (1988) 85:2444.
27. Pennefather, P., Lancaster, B., Adams, P. R. & Nicoll, R. A., Proc. Natl. Acad. Sci. (1985) 82:040-3044.
28. Pessia et al., EMBO J. (1996) 15:2980-2987.
- 20 29. Robertson, G. A., Warmke, J. W. & Ganetzky, B., Neuropharmacol. (1996) 35:41-850.
30. Rossolini et al., Mol. Cell. Probes (1994) 8:91-98.
31. Sanguinetti, M. C., Jiang, C., Curran, M. E. & Keating, M. T., Cell (1995) 81:99-307.
- 25 32. Sanguinetti et al., Nature (1996) 384:80-83.
33. Sanguinetti, M. C. & Jurkiewicz, N. K., J. Gen. Physiol. (1990) 96:95-215.
34. Shi et al., Neuron (1996).16(4):843-852.
35. Shi, W., Wymore, R. S., Wang, H. -S, Pan, Z., Cohen, I. S., McKinnon, D. & Dixon, J. E., J. Neurosci. (1997) 17:423-9432.
- 30 36. Smith & Waterman, Adv. Appl. Math. (1981) 2:482.

37. Spector, P. S., Curran, M. E., Zou, A., Keating, M. T. & Sanguinetti, M. C., J. Gen. Physiol. (1996) 107:11-619.
38. Terlau, H., Ludwig, J., Steffan, R., Pongs, O., Stuhmer, W. & Heinemann, S. H., Pflugers Arch. (1996) 432:301-312.
- 5 39. Terlau, H., Heinemann, S. H., Stuhmer, W., Pongs, O. & Ludwig, J., J. Physiol. (1997) 502:37-543.
40. Thompson, J. D., Higgins, D. G. & Gibson, T. J., Nucleic Acids Res. (1994) 22:673-4680.
41. Titus, S. A., Warmke, J. W. & Ganetzky, B., J. Neurosci.
10 (1997) 17:85-881.
42. Tijssen, Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Probes, "overview of principles of hybridization and the strategy of nucleic acid assays" (1993)
- 15 43. Wang, H.-S. & McKinnon, D., J. Physiol. (1995) 485:19-335.
44. Wang, X., Reynolds, E. R., Deak, P. & Hall, L. M., J. Neurosci. (1997) 17:82-890.
45. Warmke, J., Drysdale, R. & Ganetzky, B., Science (1991)
20 252:560-1562.
46. Warmke, J. W. & Ganetzky, B., Proc. Natl. Acad. Sci. (1994) 91:438-3442.
47. Wei, A., Jegla, T. & Salkoff, L., Neuropharmacol. (1996) 35:805-829.
- 25 48. U.S. Patent No. 5,670,335
49. U.S. Patent No. 5,776,734.

DETAILED DESCRIPTION OF THE INVENTION

INTRODUCTION

The present invention provides for the first time
30 three nucleic acids encoding respectively *elk1*, *elk2* or *eag2* identified and cloned from rat and human tissue. The

polypeptides encoded by *elk1*, *elk2* or *eag2* are members of the voltage-gated *eag*-like family of potassium channel units (*elk*). Members of this family are polypeptides that are alpha subunits of slowly activated outward rectifier potassium channels. Outward rectifier potassium channels have significant roles in maintaining the resting potential and in controlling excitability of a cell.

The invention also provides methods of screening for modulators, activators, and inhibitors of inward rectifier potassium channels that contain a subunit selected from the group consisting of *elk1*, *elk2* and *eag2*. Such modulators of outward rectifier channel activity are useful for treatment of hypertension, acute renal failure, chronic renal failure, diabetes insipidus, diabetic nephropathy, hypothyroidism, hyperthyroidism, goiter, hypoparathyroidism, hyperparathyroidism, pancreatic insufficiency, diabetes, cystic fibrosis, sialorrhea, and salivary insufficiency.

Furthermore, the invention provides assays for *elk1*, *elk2* or *eag2* activity where for *elk1*, *elk2* or *eag2* acts as a direct or indirect reporter molecule. Such uses of for *elk1*, *elk2* or *eag2* as a reporter molecule in assay and detection systems have broad applications, e.g., *elk1*, *elk2* or *eag2* can be used as a reporter molecule to measure changes in potassium concentration, in vitro, in vivo, and ex vivo, membrane potential, current flow, ion flux, transcription, signal transduction, receptor-ligand interactions, second messenger concentrations. In one embodiment, *elk1*, *elk2* or *eag2* can be used as an indicator of current flow in a particular direction (outward potassium flow), and in another embodiment, *elk1*, *elk2* or *eag2* can be used as an indirect reporter via attachment to a second reporter molecule such as green fluorescent protein. The invention provides for methods of

detecting elk1, elk2 or eag2 nucleic acid and protein expression allows investigation of channel diversity provided by elk1, elk2 or eag2 and the regulation/modulation of heteromeric channel activity provided by elk1, elk2 or eag2 ,
5 as well as disease diagnosis for conditions such as hypertension, acute renal failure, chronic renal failure, diabetes insipidus, diabetic nephropathy, hypothyroidism, hyperthyroidism, goiter, hypoparathyroidism, hyperparathyroidism, pancreatic insufficiency, diabetes,
10 cystic fibrosis, sialorrhea, and salivary insufficiency. Finally, the invention provides for a method of screening for mutations of elk1, elk2 or eag2 genes or proteins. The invention includes, but is not limited to, methods of screening for mutations in elk1, elk2 or eag2 with the use of
15 a computer. Similarly, the invention provides for methods of identifying the three-dimensional structure of elk1, elk2 or eag2 , as well as the resulting computer readable images or data that comprise the three dimensional structure of elk1, elk2 or eag2. Other methods for screening for mutations of
20 elk1, elk2 or eag2 genes or proteins include high density oligonucleotide arrays, PCR, immunoassays and the like. Functionally, each of the three elk1, elk2 or eag2 polypeptide is an alpha subunit of an slowly activated outward rectifier potassium channel. Such outward rectifier channels are
25 heteromeric or homomeric and contain typically contain four alpha subunits or monomers each with two transmembrane domains. Outward rectifier potassium channels comprising elk1, elk2 or eag2 can be heteromeric and may contain one or more alpha subunits of elk1, elk2 or eag2 along with one or more
30 other alpha subunits from the EAG-like family. Each of elk1, elk2 or eag2 can also comprise a homomeric slowly activated outward rectifier channel. The presence of elk1, elk2 or eag2

in an slowly activated outward rectifier potassium channel modulates the activity of the heteromeric channel and thus enhances channel diversity.

Structurally, the nucleotide sequence of elk1 (SEQ ID No:1) encodes a polypeptide of approximately 1102 amino acids with a predicted molecular weight of approximately 123 kDa (SEQ ID No:2) and a predicted range of 100-150 kDa.

Specific regions of the elk1 nucleotide and amino acid sequence may be used to identify polymorphic variants, homologues, and alleles of elk1. This identification can be made in vitro, e.g., under stringent hybridization conditions and sequencing, or by using the sequence information in a computer system for comparison with other nucleotide sequences. Sequence comparison can be performed using any of the sequence comparison algorithms discussed below. Antibodies that bind specifically to elk1 can also be used to identify alleles and polymorphic variants.

Polymorphic variants and alleles of elk1 can be confirmed by coexpressing the putative elk1 polypeptide and examining whether it forms a heteromeric slow activated outward rectifier potassium channel, when co-expressed with another member of the EAG-like family such as elk2. This assay is used to demonstrate that a protein having about 80% or greater, preferably 90% or greater amino acid identity to elk1 shares the same functional characteristics as elk1 and is therefore a species of elk1. Typically, elk1 having the amino acid sequence of SEQ ID No:2 is used as a positive control in comparison to the putative elk 1 protein to demonstrate the identification of a polymorphic variant or allele of elk1.

Similarly, polymorphic variants or alleles of elk2 or eag2 may be identified. For elk2, the partial amino acid

sequence SEQ ID NO:3 may be used. For EAG2, the partial amino acid sequence SEQ ID NO:4 may be employed.

5 elk1 nucleotide and amino acid sequence information may also be used to construct models of a heteromeric slowly activated outward rectifier potassium channels in a computer system. These models are subsequently used to identify compounds that can activate or inhibit heteromeric slowly activated outward rectifier potassium channels comprising elk1. Such compounds that modulate the activity of channels
10 comprising elk1 can be used to investigate the role of elk1 in modulation of channel activity and in channel diversity.

The partial amino acid sequences for elk2 and eag2 may also be used in like manner.

The isolation of biologically active elk1, elk2 and
15 eag2 for the first time provides a means for assaying for inhibitors and activators of heteromeric slowly activated outward rectifier potassium channels that comprise elk1, elk2 or eag2 subunits. Biologically active elk1, elk2 or eag2 is useful for testing modulators, inhibitors, and activators of
20 slowly activated outward rectifier potassium channels comprising subunits of elk1, elk2 or eag2 and other eag-like members using in vivo and in vitro expression that measure, e.g., changes in voltage or current. Such activators and inhibitors identified using a slowly activated outward
25 rectifier potassium channel comprising at least one elk1, elk2 or eag2 subunit can be used to further study slowly activated outward rectification, channel kinetics and conductance properties of heteromeric channels. Such activators and inhibitors are useful as pharmaceutical agents for treating
30 disorders such as hypertension, acute renal failure, chronic renal failure, diabetes insipidus, diabetic nephropathy,

hypothyroidism, hyperthyroidism, goiter, hypoparathyroidism, hyperparathyroidism, pancreatic insufficiency, diabetes, cystic fibrosis, sialorrhea, and salivary insufficiency.

Methods of detecting elk1, elk2 or eag2 and expression of

5 channels comprising elk1, elk2 or eag2 are also useful for diagnostic applications. For example, chromosomal

localization of elk1, elk2 or eag2 can be used to identify diseases caused by and associated with elk1, elk2 or eag2 .

Methods of detecting elk1, elk2 or eag2 are also useful for

10 examining the role of elk1, elk2 or eag2 in channel diversity and modulation of channel activity.

Definitions

As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

15 The phrase "outward rectifier" activity or "outward rectification" refers to a characteristic of a potassium-channel allows potassium outflux, with little potassium influx. For example, potassium ions flow outward through such channels when the membrane potential is negative to E_K , while

20 at more positive membrane potentials, inward currents may be diminished (see, e.g., Pessia et al., EMBO J. 15:2980-2987 (1996)) E_K is the membrane potential for potassium, the combination of the voltage potential and $[K^+]$ potential at which there is no net flow of potassium ion. This value (-98

25 mV) is also known as the "reversal potential" or the "Nernst" potential for potassium. Typically, the channel is composed of four subunits and the channel can be heteromeric or homomeric. The characteristic of outward rectification can be measured by a variety of techniques for measuring changes in

30 current flow and ion flux through a channel, e.g., by changing the $[K^+]$ of the external solution and measuring the activation potential of the channel current (see, e.g., U.S. Patent No.

5,670,335), by measuring current with patch clamp techniques under different conditions, and by measuring ion flux with radiolabeled tracers or voltage-sensitive dyes under different conditions.

5 A "beta subunit" is a polypeptide monomer that is an auxiliary subunit of a cation-channel composed of alpha subunits; however, beta subunits alone cannot form a channel (see, e.g., U.S. Patent No. 5,776,734). Beta subunits are known, for example, to increase the number of channels by
10 helping the alpha subunits reach the cell surface, change activation kinetics, and change the sensitivity of natural ligands binding to the channels. Beta subunits can be outside of the pore region and associated with alpha subunits comprising the pore region. They can also contribute to the
15 external mouth of the pore region.

 "elk1" refers to a polypeptide that is a subunit of an slowly activated outward rectifier potassium channel and a member of the EAG family of potassium channels. "elk1" therefore refers to polymorphic variants, alleles, mutants,
20 and closely related interspecies variants that: (1) have amino acid sequence identity of at least 60% , preferably about 80-90%, to elk1; or (2) have a nucleic acid sequence that specifically hybridize under stringent hybridization conditions to a sequence of about 17-25 base pairs selected
25 from SEQ ID No:1 or a conservatively modified variant thereof; or (4) are amplified by primers that specifically hybridize under stringent hybridization conditions to the same sequence as a primer set consisting of SEQ ID No:5 and SEQ ID No:6.

 "elk2" therefore refers to polymorphic variants,
30 alleles, mutants, and closely related interspecies variants that: (1) have amino acid sequence identity of at least 60% ,

preferably about 80-90%, to elk2; or (2) have a nucleic acid sequence that specifically hybridize under stringent hybridization conditions to a sequence of about 17-25 base pairs selected from from SEQ ID No:13 or a conservatively modified variant thereof; or (4) are amplified by primers that specifically hybridize under stringent hybridization conditions to the same sequence as a primer set consisting of SEQ ID No:9 and SEQ ID No:10.

"eag2" therefore refers to polymorphic variants, alleles, mutants, and closely related interspecies variants that: (1) have amino acid sequence identity of 50-90% , preferably about 80-90%, to eag2; or (2) have a nucleic acid sequence that specifically hybridize under stringent hybridization conditions to a sequence of about 17-25 base pairs selected from sequence SEQ ID No:14 or a conservatively modified variant thereof; or (4) are amplified by primers that specifically hybridize under stringent hybridization conditions to the same sequence as a primer set consisting of SEQ ID No:5 and SEQ ID No:6.

The phrase "functional effects" in the context of assays for testing compounds that may affect "elk1", "elk2" or "eag2" channels includes the determination of any parameter that is indirectly or directly under the influence of the "elk1", "elk2" or "eag2" channel. It includes changes in ion flux, membrane potential, current flow, transcription, G-protein binding, phosphorylation or de-phosphorylation, signal transduction, receptor-ligand interactions, second messenger concentrations (e.g., cAMP, IP3, or intracellular Ca²⁺), as measured in vitro, in vivo, and ex vivo, and also includes other physiologic effects such increases or decreases of neurotransmitter or hormone release.

By "determining the functional effect" is meant assays for a compound that increases or decreases a parameter that is indirectly or directly under the influence of "elk1", "elk2" or "eag2". Such functional effects can be measured by any means known to those skilled in the art, e.g., patch clamping, voltage-sensitive dyes, whole cell currents, radioisotope efflux, inducible markers, oocyte or tissue culture cell expression of elk1, elk2 or eag2; transcriptional activation; ligand binding assays; voltage, membrane potential and conductance changes; ion flux assays; changes in intracellular second messengers such as cAMP and inositol triphosphate (IP3); changes in intracellular calcium levels; neurotransmitter release, and the like.

"Inhibitors," "activators," and "modulators" of the eag-like slowly activated outward rectifying potassium channels comprising elk1, elk2 or eag2 refer to modulator molecules identified using in vitro and in vivo assays for channel function. Inhibitors are compounds that decrease, block, prevent, delay activation, inactivate, desensitize, or down regulate the channel. Activators are compounds that increase, open, activate, facilitate, enhance activation, sensitize or up regulate channel activity. Modulators include naturally occurring and synthetic ligands, antagonists, agonists, small chemical molecules and the like. Assays for inhibitors and activators include, e.g., coexpressing a elk1 subunit with another eag-like alpha subunit in cells or cell membranes, applying putative modulator compounds, and then measuring flux of ions through the eag-like channel and determining the functional effect of the modulator as described above.

"Biologically active" "elk1", "elk2" or "eag2" refers to "elk1", "elk2" or "eag2" that comprises a potassium channel

having slowly activated outward rectifier activity tested as described above. Typically, the potassium channel is heteromeric and contains at least one, preferably two subunits of elk1 or elk2 or eag2 and subunits of another eag-like family member such as eag1.

The terms "isolated" "purified" or "biologically pure" refer to material that is substantially or essentially free from components which normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein that is the predominant species present in a preparation is substantially purified. In particular, an isolated elk1 nucleic acid is separated from open reading frames that flank the elk1 gene and encode proteins other than elk1. The term "purified" denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Particularly, it means that the nucleic acid or protein is at least 85% pure, more preferably at least 95% pure, and most preferably 99% pure.

"Nucleic acid" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs).

Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. The term nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide, and polynucleotide.

The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an analog or mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. Polypeptides can be modified, e.g., by the addition of carbohydrate residues to form glycoproteins. The terms "polypeptide," "peptide" and "protein" include glycoproteins, as well as nonglycoproteins.

The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the generic code. Synthetic amino acids include naturally occurring amino acids that are modified, e.g., hydroxyproline, carboxyglutamate, and o-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group., e.g., homoserine, norleucine, methionine sulfoxide, and methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the

general chemical structure of an amino acid, but that functions in a manner similar o a naturally occurring amino acid.

Amino acids may be referred to herein by either their
5 commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides may be referred to by their commonly acceptd single-letter codes (A, T, G, C, U, etc.).

"Conservatively modified variants" applies to both
10 amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to
15 essentially identical sequences. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzner et al., Nucleic Acid Res. 19:5081 (1991);
20 Ohtsuka et al., J. Biol. Chem. 260:260S-2608 (1985); Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)). Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For
25 instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon in an amino acid herein, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of
30 conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of

skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule.

5 Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein
10 sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing
15 functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants and alleles of the invention.

The following groups each contain amino acids that are
20 conservative substitutions for one another:

- 1) Alanine (A), Glycine (G);
 - 2) Serine (S), Threonine (T);
 - 3) Aspartic acid (D), Glutamic acid (E);
 - 4) Asparagine (N), Glutamine (Q);
 - 25 5) Cysteine (C), Methionine (M);
 - 6) Arginine (R), Lysine (K), Histidine (H);
 - 7) Isoleucine (I), Leucine (L), Valine (V); and
 - 8) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).
- 30 (see, e.g., Creighton, Proteins (1984) for a discussion of amino acid properties).

Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, see, e g., Alberts et al., Molecular Biology of the Cell (3rd ed., (1994) and Cantor & Schimmel, Biophysical Chemistry Part I: The Conformation of Biological Macromolecules (1980).

"Primary structure" refers to the amino acid sequence of a particular peptide. "Secondary structure" refers to locally ordered, three dimensional structures within a polypeptide.

These structures are commonly known as domains. Domains are portions of a polypeptide that form a compact unit of the polypeptide and are typically 50 to 350 amino acids long. Typical domains are made up of sections of lesser organization such as stretches of β -sheet and α -helices. "Tertiary structure" refers to the complete three dimensional structure of a polypeptide monomer. "Quaternary structure" refers to the three dimensional structure formed by the non-covalent association of independent tertiary units

A "label" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include ^{32}P , fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins for which antisera or monoclonal antibodies are available (e.g., the polypeptide of SEQ ID No:1 can be made detectable, e.g., by incorporating a radiolabel into the peptide, and used to detect antibodies specifically reactive with the peptide).

As used herein a "nucleic acid probe or oligonucleotide" is defined as a nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through

complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (i.e., A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in a probe may be joined by a linkage other than a phosphodiester bond, so long as it does not interfere with hybridization. Thus, for example, probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. It will be understood by one of skill in the art that probes may bind target sequences lacking complete complementarily with the probe sequence depending upon the stringency of the hybridization conditions. The probes are preferably directly labeled as with isotopes, chromophores, lumiphores, chromogens, or indirectly labeled such as with biotin to which a streptavidin complex may later bind. By assaying for the presence or absence of the probe, one can detect the presence or absence of the select sequence or subsequence.

A "labeled nucleic acid probe or oligonucleotide" is one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the probe may be detected by detecting the presence of the label bound to the probe.

The term "recombinant" when used with reference, e.g., to a cell, or nucleic acid, protein or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non recombinant) form of the cell or

express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.

A "promoter" is defined as an array of nucleic acid control sequences that direct transcription of a nucleic acid.

5 As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand
10 base pairs from the start site of transcription. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation. The term "operably
15 linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs
20 transcription of the nucleic acid corresponding to the second sequence.

The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, the
25 nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein indicates that the protein comprises two
30 or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

An "expression vector" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector
5 can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.

The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences,
10 refer to two or more sequences or subsequences (i.e., a human elk1 monomer tail region) that are the same or have a specified percentage of amino acid residues or nucleotides (i.e., 80% identity, preferably 85%, 90%, or 95% identity) that are the same, when compared and aligned for maximum
15 correspondence over a comparison window, as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Such sequences are then said to be "substantially identical." This definition also refers to the complement of a test sequence. Preferably, the percent
20 identity exists over a region of the sequence that is at least about 25 amino acids in length, more preferably over a region that is 50 or 100 amino acids in length.

For sequence comparison, one sequence acts as a reference sequence, to which test sequences are compared.

25 When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, as described herein, or alternative parameters can be
30 designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program

parameters.

A "comparison window," as used herein, includes reference to a segment of contiguous positions having a length of at least about 25 nucleotides, usually about 50 to about 5 200 nucleotides, more usually about 100 to about 150 nucleotides in which a sequence may be compared to a reference sequence after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for 10 comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat 'l. Acad. Sci. USA 85:2444 15 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, S75 Science Dr., Madison, WI), or by manual alignment and visual inspection.

One example of a useful algorithm is PILEUP. PILEUP 20 creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a tree or dendrogram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the 25 progressive alignment method of Feng & Doolittle, J. Mol. Evol. 35:35 1-360 (1987). The method used is similar to the method described by Higgins & Sharp, CABIOS 5:151-153 (1989). The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino-acids. The multiple 30 alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most

related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. Using PILEUP, a reference sequence is compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps. PILEUP can be obtained from the GCG sequence analysis software package, e.g., version 7.0 (Devereaux et al., Nucleic Acids Res. 12:387-39S (1984)).

Another example of algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul et al., J. Mol. Biol. 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncti.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short-words of length W in the query sequence, which either match or satisfy some positive valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extension of the word hits in each direction are halted when: the cumulative alignment

score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The
5 BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10,
10 M=5, N=-4, and a comparison of both strands.

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat 'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST
15 algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a
20 comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.

An indication that two nucleic acid sequences or polypeptides are substantially identical is that the
25 polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example,
30 where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two

molecules or their complements hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleotide sequences are substantially identical is that the same primers can be used to amplify both sequences.

The phrase "selectively (or specifically) hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA).

The phrase "stringent hybridization conditions" refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acid, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Probes, "overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength pH. The T_m is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T_m , 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or

other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background, preferably 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5X SSC, and 1% SDS, incubating at 42°C, or, 5X SSC, 1% SDS, incubating at 65°C, with a wash in 0.2X SSC, and 0.1% SDS at 65°C.

Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary "moderately stringent hybridization conditions" include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 1X SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency.

"Antibody" refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy

chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.

An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chains respectively.

Antibodies exist, e.g., as intact immunoglobulins or as a number of well characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)'₂: a dimer of Fab which itself is a light chain joined to V_H-C_H1 by a disulfide bond. The F(ab)'₂ may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F(ab)'₂ dimer into an Fab' monomer. The Fab' monomer is essentially an Fab with part of the hinge region (see Fundamental Immunology (Paul ed., 3d ed. 1993)). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (see, e.g., McCafferty et al., Nature 348:552554 (1990)).

An "anti-elk1 " antibody is an antibody or antibody fragment that specifically binds a polypeptide encoded by the elk1 gene, cDNA, or a subsequence thereof. Similarly, an anti-elk2 antibody is an antibody or antibody fragment that specifically binds a polypeptide encoded by the elk2 gene, cDNA, or a subsequence thereof and an anti-eag2 antibody is an antibody or antibody fragment that specifically binds a polypeptide encoded by the eag2 gene, cDNA, or a subsequence thereof .

A "chimeric antibody" is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity.

The term "immunoassay" is an assay that uses an antibody to specifically bind an antigen. The immunoassay is characterized by the use of specific binding properties of a particular antibody to isolate, target, and/or quantify the antigen.

The phrase "specifically (or selectively) binds" to an antibody or "specifically (or selectively) immunoreactive with," when referring to a protein or peptide, refers to a binding reaction that is determinative of the presence of the protein in a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the

specified antibodies bind to a particular protein at least two times the background and do not substantially bind in a significant amount to other proteins present in the sample.

Specific binding to an antibody under such conditions may

5 require an antibody that is selected for its specificity to a particular protein. For example, polyclonal antibodies raised to rat elk1 with the amino acid sequence of the tail region encoded in SEQ ID No:2 can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive

10 with the tail region of rat elk1 and not with other proteins, except for polymorphic variants and alleles of rat elk1. This selection may be achieved by subtracting out antibodies that cross react with molecules such as human elk1 and other elk molecules such as elk2. A variety of immunoassay formats may

15 be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual (1988), for a

20 description of immunoassay formats and conditions that can be used to determine specific immunoreactivity). Typically a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 to 100 times background.

25 The phrase "selectively associates with" refers to the ability of a nucleic acid to "selectively hybridize" with another as defined above, or the ability of an antibody to selectively (or specifically) bind to a protein, as defined above.

30 By "host cell" is meant a cell that contains an expression vector and supports the replication or expression of the expression vector. Host cells may be prokaryotic cells

such as *E. coli*, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells such as CHO, HeLa and the like.

"Biological sample" as used herein is a sample of biological tissue or fluid that contains *elk1* or nucleic acid encoding *elk1* protein. Such samples include, but are not limited to, tissue isolated from humans. Biological samples may also include sections of tissues such as frozen sections taken for histological purposes. A biological sample is typically obtained from a eukaryotic organism, preferably eukaryotes such as fungi, plants, insects, protozoa, birds, fish, reptiles, and preferably a mammal such as rat, mice, cow, dog, guinea pig, or rabbit, and most preferably a primate such as chimpanzees or humans.

Isolation of cDNA clones

According to the present invention, three rat *eag*-like genes, *elk1* and *elk2*, and *eag2* were isolated by PCR amplification of cDNAs from rat brain and SCG cDNA. For *elk1* degenerate primers directed against the S1 and S5 regions were used. For *elk2*, the *elk1* sequence was used to identify similar sequences in a GenBank search. Two overlapping expressed sequence tags were found to encode a closely related channel (GenBank accession numbers R35526 and R73353). These fragments encompassed part of the cytoplasmic amino terminal domain through to the S2 region. The complementary oligonucleotide sequences derived from these sequences were used to amplify cDNA clones from rat brain and SCG cDNA.

Based on the sequences of the cDNAs obtained, the deduced amino acid sequence of *elk1* (SEQ ID NO:2) and a partial amino acid sequence of *elk2* (SEQ ID NO:3) were determined.

Using the same primers for isolating the partial *elk1*

cDNA, the *eag2* gene was initially identified by PCR amplification from rat brain cDNA and a partial amino acid sequence of *eag2* (SEQ ID NO:4) was determined.

RNA was prepared from sympathetic ganglia and brain using the *RNase* protection assay. Full length *elk1* and *eag1* cRNA transcripts were synthesized *in vitro*. The full length rat *elk1* cDNA was isolated as described. The full length rat *eag1* cDNA was amplified from rat SCG cDNA using the Expand High Fidelity PCR system. Expression was conducted in *Xenopus* oocytes. The details of the procedures used are described hereinbelow.

The human genes for *elk1*, *elk2* and *eag2* may be obtained by searching the GenBank EST database using the corresponding rat gene sequences, SEQ ID NO:1, SEQ ID NO:13 or SEQ ID NO:14, either with the BLAST or PILEUP programs. The search identifies EST from human tissues that are homologous with the rat *elk1*, *elk2* or *eag2* gene. The region having a sequence that is the most homologous with the rat *elk1* *elk2* or *eag2* gene is analyzed to select three sets of primers. In accordance with the procedures described herein below, one of the three primers is used to synthesize cDNA respectively for human *elk1*, *elk2* and *eag2* gene from homogenized human fetal brain, human adrenal and human stellate ganglia mRNA. The entire open reading frame of the human *elk1* gene is then determined using RACE PCR (Frohman, 1994) using the other two EST specific primers as the initial anchor oligonucleotides. Several rounds RACE may be required to obtain the complete open reading frame of the human *elk1*, *elk2* and *eag2* respectively.

A systematic search for new members of the *EAG* gene family was conducted using two different methods: i) novel

genes were isolated using degenerate primers combined with PCR amplification of cDNAs, ii) novel genes were identified in searches of GenBank and cDNAs then isolated by PCR. Three new genes were identified.

5 elk1

The *elk1* gene was initially identified using the following degenerate primers directed against the S1 and S5 regions to PCR amplify partial cDNA clones from rat brain and SCG cDNA.

10 Forward: TTYAARRCNRYNTGGGAYTGG (SEQ ID NO:5)

Reverse: RTACCADATRCANGCNAGCCARTG (SEQ ID NO:6)

An initial sequence encompassing the entire open reading frame of the *elk1* gene was determined by performing 5' and 3' RACE PCR (Frohman, 1994) using initial anchor
15 oligonucleotides complementary to the partial *elk1* cDNA clone. Obtaining a sequence encompassing a complete open reading frame required several rounds of RACE in both directions using SCG cDNA as a template for amplification.

Once cDNAs were obtained that extended beyond both the
20 5' and 3' ends of the open reading frame, oligonucleotides complementary to non-coding regions at either end of the coding sequence were designed. Multiple full-length cDNA clones were amplified in independent PCR reactions from rat SCG cDNA using the Expand High Fidelity PCR system
25 (Boehringer-Mannheim, Indianapolis, IN). The following oligonucleotides were used to amplify full-length cDNA clones, giving a 52 b.p. and 381 b.p. 5' and 3' UTR respectively.

forward: CGGGATCCTTGTGGACAAAC (SEQ ID NO:7)

reverse: TTCAGGAATGACAACCAGGC (SEQ ID NO:8)

30 Two independent clones were sequenced, in their entirety, using a combination of manual and automatic

sequencing. Differences between the two sequences were resolved by partial sequencing of a third independent full-length cDNA clone. Sequence alignment of the deduced amino acid sequence was performed using the ClustalW program

5 (Thompson et al, Nucleic Acids Res. (1994) 22:673-4680. The cDNA sequence of the *elk1* gene is shown in Fig. 3.

elk2

The rat *elk2* gene was initially identified by searching GenBank using the *elk1* sequence. Two overlapping
10 expressed sequence tags were found to encode a closely related channel (GenBank accession numbers R35526 and R73353). These fragments encompassed part of the cytoplasmic amino terminal domain through to the S2 region. The following complementary oligonucleotide sequences derived from these sequences were
15 used to amplify cDNA clones from rat brain and SCG cDNA.

forward: GTGATACCCATAAAGAATGAG (SEQ ID NO:9)

reverse: CGGAAATTCAGCACAAATGTC (SEQ ID NO:10)

The *elk2* sequence is

AAGGGGGAGG TGGCCCTCTT CCTGGTCTCT CACAAGGACA TCAGTGAGAC
20 CAAGAACCGA GGAGGCCCTG ACAACTGGAA GGAGAGAGGT GGTGGCCGAC
GCAGATATGG TCGGGCAGGA TCCAAAGGCT TTAATGCCAA TCGGAGGCGC
AGCCGGGCGG TTCTCTACCA CCTCTCTGGT CACCTGCAGA AACAAACCCAA
GGGCAAGCAC AAACCTCAATA AGGGTGTGTT TGGAGAGAAG CCAAATTTGC
CCGAATATAA AGTCGCTGCT ATCCGGAAGT CACCCTTTAT CCTGCTGCAC
25 TGTGGGGCTC TGAGAGCCAC CTGGGATGGC TTCATCCTGC TCGCCACGCT
CTACGTGGCT GTCAGTGTGC CATAACGCGT GTGTGTGAGC ACAGCACGGG
AGCCCAGTGC TGCCCGTGGC CCACCTAGTG TCTGTGACCT GGCCGTGGAA
GTCCTCTTCA TCTT (SEQ ID NO:13)

The deduced amino acid sequence of *elk2* is:

KGEVALFLVS HKDISETKNR GGPDNWKERG GGRRRYGRAG SKGFNANRRR
SRAVLYHLSG HLQKQPKGKH KLNKGVFGEK PNLPEYKVAA IRKSPFILLH
CGALRATWDG FILLATLYVA VTPVYSVCVS TAREPSAARG PPSVCDLAVE
VLFI (SEQ ID NO:3)

5 The *elk2* gene was clearly a member of a subfamily of
mammalian *elk* genes. The *elk2* deduced amino acid sequence was
52% identical to *elk1* and only 27% and 29% identical to rat
erg1 and *EAG1* respectively over the region shown above.

The rat *elk2* gene was also used to search the GenBank
10 human EST to obtain the human *elk2* gene, and *elk2* polypeptide.
eag2

The *eag2* gene was initially identified by PCR
amplification from rat brain cDNA using the same primers as
were used to isolate the partial rat *elk1* cDNA. The reported
15 sequence encompasses a region between S1 and S5.

The *eag2* sequence is:

GTGATTTTAA TTCTTACCTT CTACACCGCC ATCATGGTTC CTTACAACGT
TTCCTTCAAA ACAAACAGA ACAATATCGC CTGGCTGGTT CTGGACAGCG
TGGTGGACGT TATTTTCTG GTGGACATCG TTTTAAACTT TCACACGACT
20 TTTGTGGGGC CGGGTGGAGA GGTCATTTCT GACCCAAAAC TCATACGGAT
GAACTATCTG AAAACTTGGT TTGTGATTGA TCTGCTGTCT TGTTTACCTT
ATGACATCAT CAATGCCTTT GAAAATGTGG ATGAGGGAAT CAGCAGTCTC
TTCAGCTCTT TAAAGGTGGT ACGCCTCTTA CGCCTGGGCC GTGTTGCTAG
GAAACTGGAC CATTACCTGG AATATGGAGC AGCGGTCCTT GTGCTCCTGG
25 TATGTGTGTT TGGACTGGTT GCC (SEQ ID NO:14)

The deduced amino acid sequence of *eag2* is:

VILILTFYTA IMVPYNVSFK TKQNNIAWLVD LSVVDVIFL VDIVLNFHTT
FVGPGGEVIS DPKLIRMNYL KTWFFVIDLLS CLPYDIINAF ENVDEGISSL
FSSLKVVRLL RLGRVARKLD HYLEYGAAVL VLLVCVFGLV A
30 (SEQ ID NO:4)

The *eag2* gene was very similar to the previously identified rat *eag* gene (Ludwig et al., 1994), being 72% identical to rat *eag* (*eag1*) at the DNA sequence level over this region. The deduced amino acid sequence of *eag2* was 92% identical to *eag1* over this region and only 42% and 45% identical to rat *elk1* and *erg1* respectively.

RNase Protection Assay

The procedures for the preparation of RNA from sympathetic ganglia and brain and the performance of the RNase protection assay were identical to those described previously. Dixon and McKinnon, Eur. J. Neurosci. (1996) 8:83-191.

All RNA samples were prepared from pooled dissections of sympathetic ganglia from young adult Sprague-Dawley rats (4-5 weeks). The superior cervical, coeliac, and superior mesenteric ganglia were used because they are relatively discrete and can be routinely identified for dissection. For RNA preparation three tissue samples were used: (i) the combined left and right SCG, (ii) the right CG and (iii) the right SCG. Ganglia were carefully dissected free of host tissue, rinsed in phosphate buffered saline and then frozen in liquid nitrogen. Frozen ganglia were then homogenized in guanidinium thiocyanate and total RNA was prepared by pelleting over a CsCl step gradient. All RNA samples were carefully quantitated by spectrophotometric analysis and the integrity of the RNA samples was confirmed by analysis on a denaturing agarose gel. Sciatic nerve RNA was prepared similarly following dissection of sciatic nerve from rat hind limb and rapid freezing in liquid N₂. RNA expression was quantitated directly from dried RNase protection gels using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA).

The RNase protection assay was performed as follows.

RNA samples were assayed as a set coming from the same group of animals. The data were obtained from independent sets of RNA samples. For each sample point 5 or 10 µg of total RNA was used in the assay. For the positive control brain or atria sample, 5 µg of total RNA was used. In experiments where the aim was to compare the level of expression of two different K channels, the RNA probes were made using two DNA templates in the same reaction mixture to minimize differences in the specific activity of the two probes. For comparisons between probes, the data were corrected for differences in specific activity of the probes by assuming that the specific activity was directly proportional to the number of UTPs in each sequence. A probe for the rat cyclophilin gene was included in the hybridization as an internal control. The cyclophilin probe had a specific activity approximately sevenfold lower than that of the K channel probes. 10 µg of yeast tRNA was used as a negative control to test for the presence of probe self-protection bands. RNA expression was quantitated directly from dried RNase protection gels that were placed in a β-counter (Betascope 603, Biogen). Specific counts for each band were determined by subtracting a background signal determined from the tRNA lane using a counting rectangle of the same size and relative location as was used for the sample band.

The following DNA templates were used for the RNase protection assays.

eag1: Encompasses nucleotides 855 to 1162 of rat *eag* (Ludwig et al, EMBO J. (1994) 13:451-4458. GenBank Accession number Z34264).

eag2: Used partial *eag2* cDNA described above (GenBank Accession number: AF073891).

elk1: Encompasses nucleotides 710 to 1177 of rat *elk1* described above (GenBank Accession number: AF061957).

elk2: Used partial *elk2* cDNA described above (GenBank Accession number: AF073892).

5 Expression in *Xenopus* Oocytes

Full-length rat *elk1* and *eag1* cRNA transcripts were synthesized in vitro. Isolation of the full-length rat *elk1* cDNA is described above. The full-length rat *eag1* cDNA was amplified from rat SCG cDNA using the Expand High Fidelity PCR
10 system (Boehringer-Mannheim, Indianapolis, IN). The following oligonucleotides were used to amplify full-length EAG1 cDNA clones:

forward : TGCTGCGGTGAGACACG (SEQ ID NO:11)

reverse : TGGTCATGTGTTTGGTGCG (SEQ ID NO:12)

15 Oocytes were prepared from mature female *Xenopus laevis* using established procedures (Colman, 1984, incorporated herein by reference). Frogs were anaesthetized in ice water containing a 0.1% solution of Tricaine. Defolliculation was performed by incubation for 2 hours in 2
20 mg/ml collagenase (Type VIII, Sigma, St. Louis, MO) in Ca²⁺-free OR2 oocyte medium with gentle agitation. Oocytes were stored in OR3 solution (50% L-15 medium (GIBCO, Gaithersburg, MD), 1 mM glutamine, 15 mM Na-HEPES (pH 7.6), 0.1 mg/ml gentamicin) at 18°C. Oocytes were injected with 50 nl of cRNA
25 (~0.3 ng/nl) using a microdispenser and a micropipette with tip diameter of 10-20 µm. Injected oocytes were incubated at 18°C for 24-48 hours prior to analysis.

Oocytes were voltage-clamped using a two-microelectrode voltage clamp. Intracellular electrodes filled
30 with 3 M KCl with resistances of 0.5-3 MΩ were used. The

standard extracellular recording solution contained: 80 mM NaCl, 5 mM KCl, 1.8 mM CaCl₂, 1 mM MgCl₂, and 5 mM Na-HEPES (pH 7.6). Data collection and analysis were performed using pClamp software (Axon Instruments, Foster City, CA). E4031 was
5 obtained from Eisai Co. Ltd. (Tokodai, Japan).

Human elk1

Two methods described below are useful for obtaining the cDNAs that extend beyond the 5' and 3' ends of the open reading frame of the human *elk1* gene.

10

Method 1

The DNA sequence for the rat *elk1* gene (SEQ ID NO:1) is used to search the GenBank data base in order to identify expressed sequence tags (EST) from human tissues that are homologous with a part of the gene. The ESTs are not be known
15 to encode any part of the human *elk1* gene.

Using the *elk1* gene (SEQ ID NO:1) and applying the BLAST program, a human EST with the highest degree of homology to the *elk1* gene is identified.

Three primers of 17-25 base pairs having at least 90%
20 homology with a region of rat *elk1* are selected from the EST sequence identified. The primer from the most 3' end of the EST is used to make cDNA from RNA isolated from human tissue. The tissue sources include, but are not restricted to, human brain, human adrenal and human stellate ganglia. cDNA
25 synthesis is performed using established techniques as described by the manufacturers of the reverse transcriptase enzyme. The temperature recommended by the manufacturer and , a higher temperature (50°C) are used to synthesize the cDNA. The higher temperature of 50°C is used to maximize the
30 specificity of the reaction for the human *elk1* gene.

The entire opening reading frame of the human *elk1* gene is obtained using 5' RACE PCR (Frohman, 1994) using the two other primers specific for the EST as the initial anchor oligonucleotides. The procedure is described for the rat *elk1* gene herein above. Obtaining a sequence encompassing a complete open reading frame may require several rounds of RACE.

The procedures for the preparation of RNA and the expression of the cDNA transcripts in *Xenopus Oocytes* are as described above for rat *elk1*.

Method 2

Degenerate oligonucleotides are used to clone a partial cDNA sequence using human brain, adrenal or stellate cDNA as a template for amplification. Initially, the primers selected as described above are directed against the core S1 to S6 region of the gene. However, other regions may also be used.

The primers selected include codons for amino acids that are specific for the *elk1* gene and not found in related genes.

The entire opening reading frame of the human *elk1* gene is determined using 5' and 3' RACE PCR (Frohman, 1994) using initial anchor oligonucleotides complementary to the partial human *elk1* cDNA clone.

Obtaining a sequence encompassing a complete open reading frame may require several rounds of RACE in both directions.

Once cDNAs are obtained that extend beyond both the 5' and 3' ends of the open reading frame, oligonucleotides are selected complementary to non-coding regions at either end of

the coding sequence. Multiple full-length cDNA clones are amplified in independent PCR reactions from human brain, adrenal or stellate cDNA using the standard amplification techniques as described the manufacturer of the DNA
5 polymerase.

Independent clones are sequenced, in their entirety, using automatic sequencing. Sequence differences are resolved by partial sequencing of an independent cDNA clone. Sequence alignment of the deduced amino acid sequence are performed
10 using the ClustalW program (Thompson et al., 1994).

Results

Isolation of Full-length *elk1* cDNA Clone

A systematic search for genes related to the *Drosophila elk* gene and the mammalian *eag* gene was conducted
15 and three new genes are identified in rat: *elk1*, *elk2* and *eag2* and in human (see Methods). Of these three genes the *elk1* gene is of the most interest since no *elk* channel had been expressed and characterized previously. In addition the rat *elk1* gene is expressed in sympathetic ganglia, a system that
20 has been well characterized both in terms of potassium channel function as well as gene expression (Dixon and McKinnon, 1996, supra; Shi et al., 1997, supra).

The deduced amino acid sequence of the *elk1* gene suggests that it encodes a protein 1,102 amino acid residues
25 in length with an estimated molecular weight of 123 kDa (Fig. 1). Assignment of the initiator methionine and the start of the open reading frame was facilitated by the high degree of similarity in this region between the *elk1* and *Drosophila elk* sequences. There were multiple stop codons in all three
30 reading frames around the selected stop codon.

The deduced elk1 amino acid sequence was 41% identical to the *Drosophila elk* sequence. Identity with other members of the EAG gene family was significantly lower, ranging from 26 to 31%. This result suggests that the elk1 gene is a mammalian equivalent of the *Drosophila elk* gene. A similar level of identity between mammalian erg genes and their *Drosophila* counterpart has been found previously to be in the range 41 to 44%. Shi et al, 1997, supra. Identity between the rat eag1 gene and the *Drosophila eag* gene is somewhat higher, however, at 51%.

There is a high degree of similarity between the elk1 deduced amino acid sequence and the erg and EAG sequences in the amino terminus, the hydrophobic core and the putative cyclic nucleotide binding domain (Fig. 1). The elk1 sequence shares the pore signature sequence GFG with both the erg and EAG channels, in contrast to most other potassium channels, which have GYG in the equivalent position (Wei et al, 1996, supra). The elk1 protein has a relatively large cytoplasmic carboxyl domain compared to the other two channels and there is a distinctive run of negatively charged residues in this region, with 11 of 12 residues being either glutamate or aspartate. A similar but much shorter sequence is seen in EAG1 in the equivalent position.

25 Functional Expression of elk1 channels

It was of interest to compare the biophysical properties of the elk1 channel with those of eag and erg channels, since all three channels share significant regions of sequence identity. eag and erg channels have one common feature, they are relatively slowly activating compared to Kv-class (*Shaker*-related) channels. This property is also shared

by the elk1 channel (Fig. 4A). The elk1 channel is one of the slowest activating EAG channels, having a time constant for activation of 676 ± 37 ms ($n = 7$) at 0 mV. The threshold for activation is around -40 mV and the conductance-voltage curve
5 can be fit with a simple Boltzmann distribution (Fig 4B: $V_n = 9.3 \pm 0.4$ mV and $k_n = -13.1 \pm 0.3$ mV ($n = 7$)).

In a simple activation protocol such as the one shown in Figure 3A, the elk1 channel has a similar waveform to eag channels: it is a slowly activating outward rectifier. he
10 elk1 channel exhibits no apparent inactivation during depolarizing voltage steps of up to several seconds, similar to the mammalian eag1 channel (Ludwig et al, 1994, supra; Robertson et al, 1996, supra). In contrast, erg channels have very fast inactivation rates, significantly faster than their
15 activation rates, which results in an apparent inward rectification at positive membrane potentials (Sanguinetti et al, 1995, supra; Spector et al, J. Gen. Physiol. (1996) 107:11-619).

One particularly striking feature of the eag channels
20 is that the rate of activation is strongly dependent upon the holding potential, activation is significantly faster from depolarized than hyperpolarized holding potentials. This suggests that during the activation process the eag channel undergoes a slow, voltage-dependent transition between at
25 least two distinct closed states before reaching the open state (Ludwig et al., 1994, supra; Robertson et al., 1996, supra). The elk1 channel shows no obvious change in the activation rate from different holding potentials, in marked contrast to the results for eag channels over a similar range
30 of holding potentials (Fig. 4C). In this respect, the elk1 channel is more similar to erg channels, which also do not exhibit a significant shift in activation rates with changes

in holding potential.

There are some other kinetic properties for which the elk1 channel is more similar to erg than eag channels. The rate of deactivation of the elk1 channel is relatively slow, with a time constant of 111 ± 7 ms ($n = 7$) at -50 mV (Fig 4D). Deactivation rates for erg channels are also very slow, with deactivation time constants in the range of 100 ms up to several seconds at -50 mV (Sanguinetti et al, 1995, supra). In marked contrast, the deactivation rate of the mammalian eag1 channel is very fast, with a time constant of 1-6 ms (Terlau et al, Pflugers Arch. (1996) 432:301-312).

Activation of the elk1 channel was strongly dependent on the pH of the external bath solution (Fig. 4E). Following acidification of the external perfusate solution, the conductance-voltage curve was shifted significantly to more positive membrane potentials (Fig. 4F). The midpoint of the activation curve was shifted from 10.4 ± 0.4 mV at pH = 7.7, to 17.0 ± 0.7 mV at pH = 7.1 ($p < 0.05$), to 28.1 ± 1.5 mV at pH = 6.6 ($p < 0.001$). The slope factor was not significantly affected by changes in external pH ($p > 0.5$). Changing the external solution to a more alkaline pH did not produce significant shifts in the activation-conductance curve (Fig. 4F). A somewhat similar dependence of activation on external pH is seen for mammalian eag channels (Terlau et al, 1996, supra), although for eag channels there is also significant slowing of the activation kinetics by acidic pH, which is not seen for elk1 channels.

The elk1 channel was almost completely resistant to the application of two common potassium channel blockers, TEA and 4-AP. Concentrations of up to 10 mM of either drug had limited or no effects on the channel. Another class of

potassium channel blockers, methanesulfonanilide drugs such as E4031, are useful rEAGents because they are apparently quite selective for cloned and native *erg* channels at concentrations less than ~10 μ M (Sanguinetti and Jurkiewicz, J. Gen. Physiol. (1990) 96:95-215). These compounds have not been tested systematically on closely related channels, however, and for this reason we examined the effects of E4031 on the *elk1* channel. E4031 had almost no effect at concentrations up to 10 μ M (Fig. 4G). Barium ions also have some potential for differentiating among the various EAG-family channels. The *elk1* channel is more sensitive than the EAG1 channel to Ba^{2+} ions, being 85% blocked by 1 mM Ba^{2+} in the external solution (Fig. 4H). In comparison, the EAG1 channel is blocked less than 40% by 1 mM Ba^{2+} (see also Terlau et al., 1996, *supra*).

eag Gene Expression in Sympathetic Ganglia

To date the functional roles of *eag*, *erg* and *elk* channels have been poorly characterized *in vivo*. One potentially useful model system to study the function of these channels is the peripheral sympathetic ganglia. For this reason, we determined the distribution of *elk* and *eag* gene expression in three sympathetic ganglia: one paravertebral ganglia, the superior cervical ganglia (SCG) and two prevertebral ganglia, the coeliac ganglia (CG) and the superior mesenteric ganglia (SMG) (Fig. 5A). The *elk1* gene is expressed in both prevertebral and paravertebral ganglia at approximately equal levels. In contrast, the *elk2* gene is not expressed at detectable levels in sympathetic ganglia, although it is robustly expressed in the brain. Both *eag* genes are expressed in sympathetic ganglia. The *eag1* gene is expressed at high levels in all three sympathetic ganglia. The *eag2* gene is only expressed at significant levels in the prevertebral ganglia, the CG and SMG.

In addition to neurons, sympathetic ganglia also contain glial cells (known as satellite cells and developmentally related to Schwann cells). To determine whether gene expression in ganglia could be due to expression in glial cells we examined *eag* gene expression in sciatic nerve, which contains a relatively pure population of Schwann cells. Two of the seven *eag* genes tested, *elk1* and *erg1* are expressed in sciatic nerve (Fig. 5B).

A summary of *EAG* gene expression in sympathetic ganglia and sciatic nerve is shown in Table 1. At least six *EAG* genes are expressed in the sympathetic ganglia and all seven *EAG* genes are expressed in at least one neuronal tissue. Two genes, *eag2* and *erg2*, are differentially expressed in sympathetic ganglia. Both genes are expressed at higher levels in prevertebral ganglia than paravertebral ganglia. The housekeeping gene cyclophilin was expressed at significantly lower levels in sciatic nerve RNA than in ganglia or brain RNA (Fig. 5B). It is possible, therefore, that mRNA levels, as a fraction of total RNA, are significantly lower in sciatic nerve than in ganglia or brain. For this reason, the relative level of *elk1* and *erg1* expression in sciatic nerve described in Table 1 may be an underestimate in comparisons between sciatic nerve and ganglia or brain.

It has been found in contrast to the *erg* genes, the *elk* genes are not expressed in heart tissue. This characteristic combined with the difference in electrophysiological characteristics should provide a tool for identifying pharmaceuticals which would block the K channels differentially. In this manner, K channel blockers which would intervene in arrhythmia without interfering with the sympathetic nervous system may be identified.

Table 1

Distribution of EAG Potassium Channel Gene Expression
in Rat Sympathetic Ganglia, Brain and Sciatic Nerve

	<u>SCG</u>	<u>CG</u>	<u>SMG</u>	<u>Brain</u>	<u>Sciatic Nerve</u>
eag1	+++	+++	+++	+++	-
eag2	+/-	+	+	++	-
erg1	+++++	+++++	+++++	+++++	+++
erg2	+	++	+++	-	-
erg3	+++	+++	+++	+++	-
elk1	+++	+++	+++	+/-	++
elk2	-	-	-	+++	-

Key:

+++++ very high, ++++ high, +++ moderate, ++ low, + very low,
+/- just detectable, - negative

Semi-quantitative analysis of the relative levels of expression of all the EAG genes was achieved by a combination of radioactive counting of individual gels and visual comparison of autoradiographs from multiple experiments. In every case the data are based on multiple independent experiments (n = 2 to 6). Data for sciatic nerve may be subject to a systematic underestimate (see Results). Data for the erg gene expression in sympathetic ganglia is adapted from Shi et al. (1997).

Discussion

The complete coding sequence of a new potassium channel gene, the rat *elk1* gene, and partial sequences for two other *eag* genes: *eag2* and *elk2* and the procedures for obtaining the human *elk1*, *eag2* and *elk2* have been provided. The *elk1* and *elk2* genes are mammalian equivalents of the *Drosophila elk* gene. When expressed in a heterologous expression system, the *elk1* channel has some similar biophysical properties compared to the related *eag* and *erg* channels, but also has some clearly distinct properties. In particular, the *elk1* channel activates very slowly and also deactivates slowly. The *elk1* channel shows little or no inactivation during sustained depolarizing voltage steps.

Identification of three new *EAG* genes in addition to the previously known genes and the demonstration that all the *eag* genes are expressed in at least some region of the nervous system raises obvious questions about the function of *EAG* channels in the mammalian nervous system. At least six *EAG* genes are expressed in sympathetic ganglia, which is a large number of related genes to be expressed in a tissue that contains a relatively homogeneous population of cells. This result suggests that *EAG* channels are functionally important with, at most, only partially overlapping functions among the different family members. To date, however, there is little convincing data on the physiological function of any of these channels in the mammalian nervous system. In *Drosophila*, mutations in the *eag* and *erg* genes produce hyperexcitability, suggesting a role for these channels in regulating neuronal electrical activity. Ganetzky and Wu, J. Neurogenetics (1983) 1:17-28; Titus et al, J. Neurosci. (1997) 17:85-881; Wang et al, J. Neurosci. (1997) 17:82-890).

Very little information is currently available on the physiological role of elk channels or the related EAG channels in mammals. Both channels have relatively positive activation curves which limit their ability to affect sub-threshold electrical excitability. They activate too slowly to affect the shape of the action potential and, even if they are neuronally expressed, it is difficult to understand how they might affect neuronal excitability. It is possible that heteromultimerization with β subunits might modify the functional properties of these channels but there is currently no direct evidence to support such a possibility. The *elk1* gene is expressed in sciatic nerve, which suggests that *elk1* channels may function in the glial cells of sympathetic ganglia rather than in neurons.

It has been suggested that EAG subunits co-assemble with more rapidly activating Kv channel subunits to produce heteromers with novel kinetic properties. The *Drosophila* eag channel appears to modify the inactivation properties of the Shaker B channel, possibly by co-assembly into a heteromeric channel (Chen et al, Neuron (1996) 17:35-542). It has yet to be shown, however, that the mammalian Kv channels can be modified by co-assembly with mammalian eag subunits. A recent report of a current expressed in human neuroblastoma cells that has striking similarities to homomeric eag channels expressed in heterologous expression systems (Meyer and Heinemann, J. Physiol. (1998) 508:9-56) suggests that mammalian eag subunits may assemble as independent channels rather than as components of heteromultimeric complexes.

In conclusion, there are a large number of EAG channels expressed in the mammalian nervous system and these channels have a wide diversity of biophysical properties. Surprisingly, the physiological function that any EAG channel

performs in the nervous system has yet to be determined. In the past, the sympathetic nervous system has proven to be a good model system in which to study potassium channels and a large number of different potassium channel currents have been identified (Brown et al, J. Auton. Nerv. Syst. (1982) 6:23-35; Pennefather et al, Proc. Natl. Acad. Sci. (1985) 82:040-3044; Belluzzi and Sacchi, , Prog. Biophys. Molec. Biol. (1991) 55:1-30; Wang and McKinnon, J. Physiol. (1995) 485:19-335). There is, however, a clear excess in the number of potassium channel genes expressed in sympathetic ganglia relative to the number of physiologically identified potassium currents. It will be technically difficult to further refine the electrophysiological techniques necessary to resolve more distinct potassium currents although single channel recordings have provided anecdotal evidence for diversity within apparently homogeneous macroscopic currents. These technical limitations may make it necessary to use genetic approaches such as gene knock-outs to establish the physiological function of the EAG channels in the mammalian nervous system.

The present invention provides the gene sequences for *elk1*, *elk2* and *eag2* to enable these genetic approaches for further refining our understanding of the K channels and their functions. The genetic and amino acid sequence information is also useful for the development of treatment methods and pharmaceuticals for the treatment of specific disease conditions. Further the present invention provides methods by which drug candidates can be screened to avoid adverse effects on the *elk1*, *elk2* and *eag2* potassium channels.

Although the invention has been described with specific embodiments and examples, they are intended to limit the scope of the invention.

We claim:

1. An isolated nucleic acid encoding a polypeptide comprising an alpha subunit forming a eag-like potassium channel having the characteristic of slowly activated outward rectification selected from the group consisting of *elk1*, *elk2* and *eag2*.
5
2. The isolated nucleic acid according to claim 1 encoding a polypeptide forming a potassium channel for which the activation time constant for outward rectification is
- 10 3. The isolated nucleic acid according to claim 2 wherein the activation time constant for outward rectification is at least 100 ms at 0 mV with a threshold activation at -40 mV.
4. The isolated nucleic acid according to claim 2 wherein
15 the activation time constant for outward rectification is 676 ± 37 ms at 0 mV with a threshold activation at -40 mV at about pH 7.
5. The isolated nucleic acid of claim 1, wherein the nucleic acid encodes a polypeptide having a molecular weight of
20 between 100 to 150 kDa.
6. The isolated nucleic acid of claim 1, wherein the polypeptide has a molecular weight of about 123 kDa.
7. The isolated nucleic acid of claim 1, wherein the nucleic acid encodes human *elk1*.
- 25 8. The isolated nucleic acid of claim 1, wherein the nucleic acid encodes rat *elk1*.
9. The isolated nucleic acid of claim 1, wherein the nucleic acid encodes human *elk2*.
10. The isolated nucleic acid of claim 1, wherein the nucleic
30 acid encodes human *eag2*.
11. The isolated nucleic acid sequence of claim 7, wherein the nucleic acid has a nucleotide sequence of SEQ ID No:1.

12. The isolated nucleic acid sequence of claim 8 wherein the nucleic acid is at least 80% homologous to SEQ ID NO:1.

13. The isolated nucleic acid of claim 7, wherein the nucleic acid is isolated from superior cervical ganglia, coeliac ganglia, superior mesenteric ganglia, foetal brain, adrenal or stellate ganglia by PCR using primers that selectively hybridize under stringent hybridization conditions to a pair of primers:

5' TTY AAR RCN RYN TGG GAY TGG 3' (SEQ ID No:5) and

3' RTA CCA DAT RCA NGC NAG CCA RTG 5' (SEQ ID No:6)

and amplified using a pair of primers:

5' CGG GAT CCT TGT GGA CAA AC 3' (SEQ ID NO:7)

3' TTC AGG AAT GAC AAC CAG GC 5' (SEQ ID NO:8)...

14. The isolated nucleic acid of claim 8 encoding a polypeptide and specifically hybridizes under stringent conditions to SEQ ID No:1.

15. The isolated nucleic acid of claim 8, wherein said nucleic acid selectively hybridizes under moderately stringent hybridization conditions to a nucleotide sequence of SEQ ID No:1.

16. The isolated nucleic acid of claim 1, wherein said nucleic acid encodes the polypeptide SEQ ID NO:3.

17. The isolated nucleic acid of claim 1, wherein said nucleic acid comprises the partial sequence SEQ ID NO:13.

18. The isolated nucleic acid of claim 15, wherein the nucleic acid is isolated from superior cervical ganglia by PCR using primers that selectively hybridize under stringent hybridization conditions to a pair of primers:

5' TTY AAR RCN RYN TGG GAY TGG 3' (SEQ ID No:5) and

3' RTA CCA DAT RCA NGC NAG CCA RTG 5' (SEQ ID No:6)

and amplified with a pair of primers:

5' GTG ATA CCC ATA AAG AAT GAG 3' (SEQ ID NO:9)

3' CGG AAA TTC AGC ACA ATG TC 5' (SEQ ID NO:10).

19. The isolated nucleic acid of claim 1, wherein said nucleic acid partially encodes the polypeptide SEQ ID NO:4.

20. The isolated nucleic acid of claim 1, wherein said nucleic acid comprises the partial sequence SEQ ID NO:14.

21. The isolated nucleic acid of claim 18, wherein the nucleic acid is isolated from brain tissue by PCR using primers that selectively hybridize under stringent hybridization conditions to a pair of primers:

5' TTY AAR RCN RYN TGG GAY TGG 3' (SEQ ID No:5) and

3' RTA CCA DAT RCA NGC NAG CCA RTG 5' (SEQ ID No:6)

and amplified by PCR using a pair of primers:

5' CGG GAT CCT TGT GGA CAA AC 3' (SEQ ID NO:7)

3' TTC AGG AAT GAC AAC CAG GC 5' (SEQ ID NO:8).

22. An isolated polypeptide forming a eag-like potassium channel having the characteristic of slowly activated outward rectification selected from the group consisting of *elk1*, *elk2* and *eag2*.

23. The isolated polypeptide according to claim 21 forming a eag-like potassium channel for which the activation time constant for outward rectification is

24. The isolated polypeptide according to claim 21 wherein the potassium channel has an activation time constant for outward rectification of 676 ± 37 ms at 0 mV with a threshold activation at -40 mV at about pH 7.

25. The isolated polypeptide of claim 21, wherein the polypeptide is rat *elk1*.

26. The isolated polypeptide of claim 21, wherein the polypeptide is human *elk1*.

27. The isolated polypeptide of claim 21, wherein the polypeptide is human elk2.
28. The isolated polypeptide of claim 21, wherein the polypeptide is human eag2.
- 5 29. The isolated polypeptide of claim 21 wherein the amino acid sequence of the polypeptide is SEQ ID NO:2.
30. The isolated polypeptide of claim 21 wherein the partial amino acid sequence of the polypeptide is SEQ ID NO:3.
31. The isolated polypeptide of claim 21 wherein the partial
10 amino acid sequence of the polypeptide is SEQ ID NO:4.
32. An expression vector comprising the nucleic acid of claim 1.
33. An expression vector comprising the nucleic acid of claim 4.
- 15 34. An expression vector comprising the nucleic acid of claim 5.
35. An expression vector comprising the nucleic acid of claim 6.
36. An expression vector comprising the nucleic acid of claim
20 7.
37. An expression vector comprising the nucleic acid of claim 16.
38. An expression vector comprising the nucleic acid of claim 19.
- 25 39. A host cell transfected with the vector of claim 31.
40. A host cell transfected with the vector of claim 32.
41. A host cell transfected with the vector of claim 33.
42. A host cell transfected with the vector of claim 34.
43. A host cell transfected with the vector of claim 35.
- 30 44. A host cell transfected with the vector of claim 36.
45. A host cell transfected with the vector of claim 37.

46. A method for identifying a compound that modulates ion flux through a slowly activated outward rectifier potassium channel selected from the group consisting of elk1, elk2, eag2, the method comprising the steps of:
- 5 (i) contacting the compound with a eukaryotic host cell or cell membrane in which has been expressed a polypeptide forming a potassium channel having the characteristic of slowly activated outward rectification; and
- 10 (ii) determining the functional effect of the compound upon the cell or cell membrane expressing the potassium channel.
47. The method of claim 38, wherein the eukaryotic host cell is *Xenopus* oocyte.
- 15 48. The method of claim 38, wherein the functional effect is determined by measuring changes in current or voltage.
49. The method of claim 38, wherein the potassium channel polypeptide is recombinant.
50. The method of claim 38, wherein the potassium channel is
- 20 heteromeric.
51. The method of claim 38, wherein the potassium channel polypeptide is human elk1.
52. The method of claim 38, wherein the potassium channel polypeptide has an amino acid sequence of SEQ ID No:2.
- 25 53. A method of detecting the presence of elk1 in mamalian tissue selected from the group consisting of superior cervical ganglia, coeliac ganglia, superior mesenteric ganglia, foetal brain, adrenal and stellate ganglia, the method comprising the steps of
- 30 (i) isolating a biological sample from the mammalian tissue,
- (ii) contacting the biological sample with a elk1

specific reagent that selectively associates with elk1;
and

(iii) detecting the level of elk1 specific reagent that
selectively associates with the sample.

- 5 54. The method of claim 52, wherein the elk1-specific reagent
is selected from the group consisting of: elk1 specific
oligonucleotide primers, and elk1 nucleic acid probes.
55. In a computer system, a method of screening for mutations
of human *eag*-like genes selected from the group
10 consisting of *elk1*, *elk2* and *eag2*, the method comprising
the steps of:
- (i) entering into the computer system a first nucleic
acid sequence encoding a slowly activated outward
rectifier potassium channel polypeptide, said first
15 nucleic acid sequence having a nucleotide sequence
selected from the group consisting of of SEQ ID No:1,
comprising partial SEQ ID NO:13, and partial SEQ ID NO:
14 and conservatively modified versions thereof;
- (ii) comparing the first nucleic acid sequence with a
20 second nucleic acid sequence having substantial identity
to the first nucleic acid sequence; and
- (iii) identifying nucleotide differences between the
first and second nucleic acid sequences.
56. The method of claim 54, wherein the second nucleic acid
25 sequence is associated with a disease state.
57. A computer readable substrate comprising the first amino
acid sequence of claim 24.
58. A computer readable substrate comprising the first amino
acid sequence of claim 25.
- 30 59. A computer readable substrate comprising the first amino
acid sequence of claim 26.

60. A computer readable substrate comprising the first amino acid sequence of claim 27.

61. In a computer system, a method for identifying a three-dimensional structure of EAG-like polypeptides selected from the group consisting of elk1, elk2, eag2, the method comprising the steps of:

(i) entering into the computer system an amino acid sequence of at least 10 amino acids of a potassium channel peptide or at least 30 nucleotides of a gene encoding the polypeptide, the polypeptide having a partial amino acid sequence selected from a group consisting of a part of SEQ ID No: 2, SEQ ID NO:3, SEQ ID NO:4 and conservatively modified versions thereof; and

(ii) generating a three-dimensional structure of the polypeptide encoded by the amino-acid sequence.

62. The method of claim 60, wherein said amino acid sequence is a primary structure and wherein said generating step includes the steps of:

(i) forming a secondary structure from said primary structure using energy terms determined by the primary structure; and

(ii) forming a tertiary structure from said secondary structure using energy terms determined by said secondary structure.

63. The method of claim 61, wherein said generating step further includes the step of forming a quaternary structure from said tertiary structure using anisotropic terms encoded by the tertiary structure.

64. The method of claim 60, further comprising the step of identifying regions of the three-dimensional structure of the protein that bind to ligands and using the regions to identify ligands that bind to the polypeptide.

65. A computer readable substrate comprising the three dimensional structure of the polypeptide of claim 24.
66. A computer readable substrate comprising the three dimensional structure of the polypeptide of claim 25.
- 5 67. A computer readable substrate comprising the three dimensional structure of the polypeptide of claim 26.
68. A computer readable substrate comprising the three dimensional structure of the polypeptide of claim 27.




Fig. 1

Fig. 2

elk1	---MPVMKGLLAPQNTFLDTIATRFDGTHSNFILANAQVAKGFPIVYCSD	47
erg1	---MPVRRGHVAPQNTFLDTIIRKFEGQSRKFIIANARVEN-CAVIYCND	46
eag1	MTMAGGRRGLVAPQNTFLENIVRRS--NDTNEVLGNAQIVD-WPIVYSND	47
elk1	<u>GFCELAGFARTEVMOKSCSCKFLFGVETNEQMLQIEKSLEEKVEFKGEI</u>	97
erg1	<u>GFCELCGYSRAEVMQRPCTCDFLHGPRTORRAAAQIAQALLGAEERKVEI</u>	96
eag1	<u>GFCKLSGYHRAEVMOKSSACSFMYGELTDKDTVEKVRQTFENYEMNSFEI</u>	97
elk1	<u>MFYKKN</u> GAPFWCLLDIVPIKNEKGDVVLFLASFKDITDTKVKITSEDKKE	147
erg1	AFYRKDGSCFLCLVDVVPVKNEGDGAVIMFILNFEVVMKDMVGSPAHDTN	146
eag1	<u>LMYKKNRTPVWFFVKIAPIRNEQDKVVLFLCTFS</u> DITA--FK-QPIKDDS	144
elk1	DRAK-----GRSR-----A	156
erg1	HRGPSTSWLASGRAKTFRLKLPALLALTARESPMRTGSTGSPGAPGAVVV	196
eag1	<u>CKG</u> -----WGKFAR-----	153
elk1	GSHFDSARRRS-----R-----	168
erg1	DVDLTPAAPSS ES LALDEVSA MD NHVAGLGPAEERRALVGPASASPVASI	246
eag1	---L T RALTSS-----R-----G-----	163
elk1	-----AVLYHISGHLO-----	179
erg1	PGPHPS P RAQSLNP D ASGSSCSLARTRSRESCASVRRASSADDIEAMRAG	296
eag1	-----VLQQLAPSVO-----	173
elk1	-----	179
erg1	ALPLPPRHASTGAMHPLRSGLLNSTSDSLVRYRTISKIPQITLNFVDLK	346
eag1	-----K	174
elk1	-----RREKNK---LKINNNVFVDKPAFPEYKVSDAK	208
erg1	<u>GDPFLASPTSDREIIAPKIKERTHN</u> VTEKVTQVLSLGADVLP EYK LOAPR	396
eag1	<u>G</u> -----ENVH KH ---SRLAEVLQ LG SDILPOYKQ EAPK	204
-----S1-----		
elk1	KSKFILLHFSTFKAGDWLILLATFYVAVTV PYN VCFIGNED--LS----	252
erg1	IHRWTILHYSPFKAVWDWLILLIVITAVFTPYSA AFLL KETEDGSQAPD	446
eag1	PPHII LHY CVFKTTTWDWIILITFYTAILV PYN VSEKTRQN-N-----	247
-----S2-----		
elk1	---TTRSTTVSDIAVEILFIIDILNFRTTYVSKSGQVIFEARSICIHVV	299
erg1	CGYACQPLAVVDLLVDIMFIVDILINFRTTYVNANEEVVSHPGRIAVHYF	496
eag1	-----VAWL V VD S IVDVIFLVDIVLNFHTTFVGPAGEVISDPKLI RM NYL	292

Fig. 2 (Cont'd)

	-----S3-----	-----S4-----	
elk1	<u>T</u> <u>T</u> <u>W</u> <u>F</u> <u>I</u> <u>I</u> <u>D</u> <u>L</u> <u>I</u> <u>A</u> <u>A</u> <u>L</u> <u>P</u> <u>F</u> <u>D</u> <u>L</u> <u>L</u> <u>Y</u> <u>A</u> <u>F</u> <u>N</u> <u>V</u> <u>T</u> <u>V</u> <u>S</u> ---	<u>L</u> <u>V</u> <u>H</u> <u>L</u> <u>L</u> <u>K</u> <u>T</u> <u>V</u> <u>R</u> <u>L</u> <u>L</u> <u>R</u> <u>L</u> <u>L</u> <u>R</u> <u>L</u> <u>L</u> <u>O</u> <u>K</u> <u>L</u> <u>D</u>	346
erg1	<u>K</u> <u>G</u> <u>W</u> <u>F</u> <u>L</u> <u>I</u> <u>D</u> <u>M</u> <u>V</u> <u>A</u> <u>A</u> <u>I</u> <u>P</u> <u>F</u> <u>D</u> <u>L</u> <u>L</u> <u>I</u> <u>F</u> <u>G</u> <u>S</u> <u>G</u> <u>S</u> <u>E</u> ----	<u>L</u> <u>I</u> <u>G</u> <u>L</u> <u>L</u> <u>K</u> <u>T</u> <u>A</u> <u>R</u> <u>L</u> <u>L</u> <u>R</u> <u>L</u> <u>V</u> <u>R</u> <u>V</u> <u>A</u> <u>R</u> <u>K</u> <u>L</u> <u>D</u>	542
eag1	<u>K</u> <u>T</u> <u>W</u> <u>F</u> <u>V</u> <u>I</u> <u>D</u> <u>L</u> <u>L</u> <u>S</u> <u>C</u> <u>L</u> <u>P</u> <u>Y</u> <u>D</u> <u>V</u> <u>I</u> <u>N</u> <u>A</u> <u>F</u> <u>E</u> <u>N</u> <u>V</u> <u>D</u> <u>E</u> <u>G</u> <u>I</u> <u>S</u> <u>S</u> <u>L</u> <u>F</u> <u>S</u> <u>S</u> <u>L</u> <u>K</u> <u>V</u> <u>V</u> <u>R</u> <u>L</u> <u>L</u> <u>R</u> <u>L</u> <u>G</u> <u>R</u> <u>V</u> <u>A</u> <u>R</u> <u>K</u> <u>L</u> <u>D</u>		342
	-	-----S5-----	
elk1	<u>R</u> <u>Y</u> <u>S</u> <u>Q</u> <u>H</u> <u>S</u> <u>T</u> <u>I</u> <u>V</u> <u>L</u> <u>T</u> <u>L</u> <u>L</u> <u>M</u> <u>S</u> <u>M</u> <u>F</u> <u>A</u> <u>L</u> <u>L</u> <u>A</u> <u>H</u> <u>W</u> <u>M</u> <u>A</u> <u>C</u> <u>I</u> <u>W</u> <u>Y</u> <u>V</u> <u>I</u> <u>G</u> <u>K</u> <u>M</u> <u>E</u> <u>R</u> <u>E</u> <u>D</u> <u>N</u> <u>S</u> <u>L</u> <u>L</u> <u>K</u> <u>W</u> <u>E</u> <u>V</u> <u>G</u> - <u>W</u> <u>L</u>		395
erg1	<u>R</u> <u>Y</u> <u>S</u> <u>E</u> <u>Y</u> <u>G</u> <u>A</u> <u>A</u> <u>V</u> <u>L</u> <u>F</u> <u>L</u> <u>L</u> <u>M</u> <u>C</u> <u>T</u> <u>F</u> <u>A</u> <u>L</u> <u>I</u> <u>A</u> <u>H</u> <u>W</u> <u>L</u> <u>A</u> <u>C</u> <u>I</u> <u>W</u> <u>Y</u> <u>A</u> <u>I</u> <u>G</u> <u>N</u> <u>M</u> <u>E</u> <u>Q</u> <u>P</u> <u>H</u> <u>M</u> <u>D</u> <u>S</u> <u>H</u> <u>I</u> <u>G</u> --- <u>W</u> <u>L</u>		588
eag1	<u>H</u> <u>Y</u> <u>I</u> <u>E</u> <u>Y</u> <u>G</u> <u>A</u> <u>A</u> <u>V</u> <u>L</u> <u>V</u> <u>L</u> <u>L</u> <u>V</u> <u>C</u> <u>V</u> <u>F</u> <u>G</u> <u>L</u> <u>A</u> <u>A</u> <u>H</u> <u>W</u> <u>M</u> <u>A</u> <u>C</u> <u>I</u> <u>W</u> <u>Y</u> <u>S</u> <u>I</u> <u>G</u> <u>D</u> <u>Y</u> <u>E</u> <u>I</u> <u>F</u> <u>D</u> <u>E</u> <u>D</u> <u>T</u> <u>K</u> <u>T</u> <u>I</u> <u>R</u> <u>N</u> <u>N</u> <u>S</u> <u>W</u> <u>L</u>		392
		-----P-----	
elk1	<u>H</u> <u>E</u> <u>L</u> <u>G</u> <u>K</u> <u>R</u> <u>L</u> <u>E</u> <u>S</u> <u>P</u> <u>Y</u> <u>Y</u> <u>G</u> <u>N</u> <u>N</u> ----- <u>T</u> <u>L</u> <u>G</u> <u>G</u> <u>P</u> <u>S</u> <u>I</u> <u>R</u> <u>S</u> <u>A</u> <u>Y</u> <u>I</u> <u>A</u> <u>A</u> <u>L</u> <u>Y</u> <u>F</u> <u>T</u> <u>L</u> <u>S</u> <u>S</u> <u>L</u> <u>T</u> <u>S</u> <u>V</u> <u>G</u> <u>F</u> <u>G</u> <u>N</u> <u>V</u>		440
erg1	<u>H</u> <u>N</u> <u>L</u> <u>G</u> <u>D</u> <u>Q</u> <u>I</u> <u>G</u> <u>K</u> <u>P</u> <u>Y</u> <u>N</u> <u>S</u> <u>S</u> <u>G</u> ----- <u>L</u> <u>G</u> <u>G</u> <u>P</u> <u>S</u> <u>I</u> <u>K</u> <u>D</u> <u>K</u> <u>Y</u> <u>V</u> <u>T</u> <u>A</u> <u>L</u> <u>Y</u> <u>F</u> <u>T</u> <u>F</u> <u>S</u> <u>S</u> <u>L</u> <u>T</u> <u>S</u> <u>V</u> <u>G</u> <u>F</u> <u>G</u> <u>N</u> <u>V</u>		632
eag1	<u>Y</u> <u>Q</u> <u>L</u> <u>A</u> <u>L</u> <u>D</u> <u>I</u> <u>G</u> <u>T</u> <u>P</u> <u>Y</u> <u>Q</u> <u>F</u> <u>N</u> <u>G</u> <u>S</u> <u>G</u> <u>S</u> <u>G</u> <u>K</u> <u>W</u> <u>E</u> <u>G</u> <u>G</u> <u>P</u> <u>S</u> <u>K</u> <u>N</u> <u>S</u> <u>V</u> <u>Y</u> <u>I</u> <u>S</u> <u>S</u> <u>L</u> <u>Y</u> <u>F</u> <u>T</u> <u>M</u> <u>T</u> <u>S</u> <u>L</u> <u>T</u> <u>S</u> <u>V</u> <u>G</u> <u>F</u> <u>G</u> <u>N</u> <u>I</u>		442
		-----S6-----	
elk1	<u>S</u> <u>A</u> <u>N</u> <u>T</u> <u>D</u> <u>A</u> <u>E</u> <u>K</u> <u>I</u> <u>F</u> <u>S</u> <u>I</u> <u>C</u> <u>T</u> <u>M</u> <u>L</u> <u>I</u> <u>G</u> <u>A</u> <u>L</u> <u>M</u> <u>H</u> <u>A</u> <u>L</u> <u>V</u> <u>F</u> <u>G</u> <u>N</u> <u>V</u> <u>T</u> <u>A</u> <u>I</u> <u>I</u> <u>Q</u> <u>R</u> <u>M</u> <u>Y</u> <u>S</u> <u>R</u> <u>W</u> <u>S</u> <u>L</u> <u>Y</u> <u>H</u> <u>T</u> <u>R</u> <u>T</u> <u>K</u> <u>D</u> <u>L</u>		490
erg1	<u>S</u> <u>P</u> <u>N</u> <u>T</u> <u>N</u> <u>S</u> <u>E</u> <u>K</u> <u>I</u> <u>F</u> <u>S</u> <u>I</u> <u>C</u> <u>V</u> <u>M</u> <u>L</u> <u>I</u> <u>G</u> <u>S</u> <u>L</u> <u>M</u> <u>Y</u> <u>A</u> <u>S</u> <u>I</u> <u>F</u> <u>G</u> <u>N</u> <u>V</u> <u>S</u> <u>A</u> <u>I</u> <u>I</u> <u>Q</u> <u>R</u> <u>L</u> <u>Y</u> <u>S</u> <u>G</u> <u>T</u> <u>A</u> <u>R</u> <u>Y</u> <u>H</u> <u>T</u> <u>O</u> <u>M</u> <u>L</u> <u>R</u> <u>V</u>		682
eag1	<u>A</u> <u>P</u> <u>S</u> <u>T</u> <u>D</u> <u>I</u> <u>E</u> <u>K</u> <u>I</u> <u>F</u> <u>A</u> <u>V</u> <u>A</u> <u>I</u> <u>M</u> <u>I</u> <u>G</u> <u>S</u> <u>L</u> <u>L</u> <u>Y</u> <u>A</u> <u>T</u> <u>I</u> <u>F</u> <u>G</u> <u>N</u> <u>V</u> <u>T</u> <u>T</u> <u>I</u> <u>F</u> <u>Q</u> <u>O</u> <u>M</u> <u>Y</u> <u>A</u> <u>N</u> <u>T</u> <u>N</u> <u>R</u> <u>Y</u> <u>H</u> <u>E</u> <u>M</u> <u>L</u> <u>N</u> <u>S</u> <u>V</u>		492
elk1	<u>K</u> <u>D</u> <u>F</u> <u>I</u> <u>R</u> <u>V</u> <u>H</u> <u>H</u> <u>L</u> <u>P</u> <u>Q</u> <u>O</u> <u>L</u> <u>K</u> <u>O</u> <u>R</u> <u>M</u> <u>L</u> <u>E</u> <u>Y</u> <u>F</u> <u>Q</u> <u>T</u> <u>T</u> <u>S</u> <u>V</u> <u>N</u> <u>N</u> <u>G</u> <u>I</u> <u>D</u> <u>S</u> <u>N</u> <u>E</u> <u>L</u> <u>L</u> <u>K</u> <u>D</u> <u>F</u> <u>P</u> <u>D</u> <u>E</u> <u>L</u> <u>R</u> <u>S</u> <u>D</u> <u>I</u> <u>T</u> <u>M</u>		540
erg1	<u>R</u> <u>E</u> <u>F</u> <u>I</u> <u>R</u> <u>F</u> <u>H</u> <u>O</u> <u>I</u> <u>P</u> <u>N</u> <u>P</u> <u>L</u> <u>R</u> <u>O</u> <u>R</u> <u>L</u> <u>E</u> <u>E</u> <u>Y</u> <u>F</u> <u>Q</u> <u>H</u> <u>A</u> <u>W</u> <u>S</u> <u>Y</u> <u>T</u> <u>N</u> <u>G</u> <u>I</u> <u>D</u> <u>M</u> <u>N</u> <u>A</u> <u>V</u> <u>L</u> <u>K</u> <u>G</u> <u>F</u> <u>E</u> <u>C</u> <u>L</u> <u>O</u> <u>A</u> <u>D</u> <u>I</u> <u>C</u> <u>L</u>		732
eag1	<u>R</u> <u>D</u> <u>F</u> <u>L</u> <u>K</u> <u>L</u> <u>Y</u> <u>Q</u> <u>V</u> <u>P</u> <u>K</u> <u>L</u> <u>S</u> <u>E</u> <u>R</u> <u>V</u> <u>M</u> <u>D</u> <u>Y</u> <u>I</u> <u>V</u> <u>S</u> <u>T</u> <u>W</u> <u>S</u> <u>M</u> <u>S</u> <u>R</u> <u>G</u> <u>I</u> <u>D</u> <u>T</u> <u>K</u> <u>K</u> <u>V</u> <u>L</u> <u>Q</u> <u>I</u> <u>C</u> <u>P</u> <u>K</u> <u>D</u> <u>N</u> <u>R</u> <u>A</u> <u>D</u> <u>I</u> <u>C</u> <u>V</u>		542
elk1	<u>H</u> <u>L</u> <u>N</u> <u>K</u> <u>E</u> <u>I</u> <u>L</u> <u>Q</u> <u>L</u> <u>S</u> - <u>L</u> <u>F</u> <u>E</u> <u>C</u> <u>A</u> <u>S</u> <u>R</u> <u>G</u> <u>C</u> <u>L</u> <u>R</u> <u>S</u> <u>L</u> <u>S</u> <u>L</u> <u>H</u> <u>I</u> <u>K</u> <u>T</u> <u>S</u> <u>F</u> <u>C</u> <u>A</u> <u>P</u> <u>G</u> <u>E</u> <u>Y</u> <u>L</u> <u>L</u> <u>R</u> <u>O</u> <u>G</u> <u>D</u> <u>A</u> <u>L</u> <u>O</u> <u>A</u> <u>I</u> <u>Y</u>		589
erg1	<u>H</u> <u>L</u> <u>N</u> <u>R</u> <u>S</u> <u>L</u> <u>L</u> <u>O</u> <u>H</u> <u>C</u> <u>K</u> <u>P</u> <u>F</u> <u>R</u> <u>G</u> <u>A</u> <u>T</u> <u>K</u> <u>G</u> <u>C</u> <u>L</u> <u>R</u> <u>A</u> <u>L</u> <u>A</u> <u>M</u> <u>K</u> <u>F</u> <u>K</u> <u>T</u> <u>T</u> <u>H</u> <u>A</u> <u>P</u> <u>P</u> <u>G</u> <u>D</u> <u>T</u> <u>I</u> <u>V</u> <u>H</u> <u>A</u> <u>G</u> <u>D</u> <u>L</u> <u>I</u> <u>T</u> <u>A</u> <u>L</u> <u>Y</u>		782
eag1	<u>H</u> <u>L</u> <u>N</u> <u>R</u> <u>K</u> <u>V</u> <u>F</u> <u>K</u> <u>E</u> <u>H</u> <u>P</u> <u>A</u> <u>F</u> <u>R</u> <u>L</u> <u>S</u> <u>D</u> <u>G</u> <u>C</u> <u>L</u> <u>R</u> <u>A</u> <u>L</u> <u>A</u> <u>M</u> <u>E</u> <u>F</u> <u>Q</u> <u>T</u> <u>V</u> <u>H</u> <u>C</u> <u>A</u> <u>P</u> <u>G</u> <u>D</u> <u>L</u> <u>I</u> <u>Y</u> <u>H</u> <u>A</u> <u>G</u> <u>E</u> <u>D</u> <u>V</u> <u>D</u> <u>S</u> <u>L</u> <u>C</u>		592
	-----cNBD-----		
elk1	<u>F</u> <u>V</u> <u>C</u> <u>S</u> <u>G</u> <u>S</u> <u>M</u> <u>E</u> <u>V</u> <u>L</u> <u>K</u> <u>D</u> <u>S</u> <u>M</u> <u>V</u> <u>L</u> <u>A</u> <u>I</u> <u>L</u> <u>G</u> <u>K</u> <u>G</u> <u>D</u> <u>L</u> <u>I</u> <u>G</u> <u>A</u> <u>N</u> <u>L</u> <u>S</u> <u>I</u> <u>K</u> <u>D</u> <u>Q</u> <u>V</u> <u>I</u> <u>K</u> <u>T</u> <u>N</u> <u>A</u> <u>D</u> <u>V</u> <u>K</u> <u>A</u> <u>L</u> <u>T</u> <u>Y</u> <u>C</u> <u>D</u> <u>L</u>		639
erg1	<u>F</u> <u>I</u> <u>S</u> <u>R</u> <u>G</u> <u>S</u> <u>I</u> <u>E</u> <u>I</u> <u>L</u> <u>R</u> <u>G</u> <u>D</u> <u>V</u> <u>V</u> <u>V</u> <u>A</u> <u>I</u> <u>L</u> <u>G</u> <u>K</u> <u>N</u> <u>D</u> <u>I</u> <u>F</u> <u>G</u> <u>E</u> <u>P</u> <u>L</u> <u>N</u> <u>L</u> <u>Y</u> <u>A</u> <u>R</u> <u>P</u> <u>G</u> <u>K</u> <u>S</u> <u>N</u> <u>G</u> <u>D</u> <u>V</u> <u>R</u> <u>A</u> <u>L</u> <u>T</u> <u>Y</u> <u>C</u> <u>D</u> <u>L</u>		832
eag1	<u>F</u> <u>V</u> <u>V</u> <u>S</u> <u>G</u> <u>S</u> <u>L</u> <u>E</u> <u>V</u> <u>I</u> <u>Q</u> <u>D</u> <u>D</u> <u>E</u> <u>V</u> <u>V</u> <u>A</u> <u>I</u> <u>L</u> <u>G</u> <u>K</u> <u>G</u> <u>D</u> <u>V</u> <u>F</u> <u>G</u> <u>D</u> <u>V</u> <u>F</u> <u>W</u> <u>K</u> <u>E</u> <u>A</u> <u>T</u> <u>L</u> <u>A</u> <u>Q</u> <u>S</u> <u>C</u> <u>A</u> <u>N</u> <u>V</u> <u>R</u> <u>A</u> <u>L</u> <u>T</u> <u>Y</u> <u>C</u> <u>D</u> <u>L</u>		642
elk1	<u>Q</u> <u>C</u> <u>I</u> <u>I</u> <u>L</u> <u>K</u> <u>G</u> <u>L</u> <u>F</u> <u>E</u> <u>V</u> <u>L</u> <u>G</u> <u>L</u> <u>Y</u> <u>P</u> <u>E</u> <u>Y</u> <u>A</u> <u>H</u> <u>K</u> <u>F</u> <u>V</u> <u>E</u> <u>D</u> <u>I</u> <u>Q</u> <u>H</u> <u>D</u> <u>L</u> <u>T</u> <u>Y</u> <u>N</u> <u>L</u> <u>R</u> <u>E</u> <u>G</u> <u>H</u> <u>E</u> <u>S</u> <u>D</u> <u>V</u> <u>I</u> <u>S</u> <u>R</u> <u>L</u> <u>S</u> <u>N</u> <u>K</u> <u>S</u>		689
erg1	<u>H</u> <u>K</u> <u>I</u> <u>H</u> <u>R</u> <u>D</u> <u>D</u> <u>L</u> <u>L</u> <u>E</u> <u>V</u> <u>L</u> <u>D</u> <u>M</u> <u>Y</u> <u>P</u> <u>E</u> <u>F</u> <u>S</u> <u>D</u> <u>H</u> <u>F</u> <u>W</u> S--- <u>S</u> <u>L</u> <u>E</u> <u>I</u> <u>T</u> <u>F</u> <u>N</u> <u>L</u> <u>R</u> <u>D</u> <u>T</u> <u>N</u> <u>M</u> <u>I</u> <u>P</u> <u>G</u> -----		872
eag1	<u>H</u> <u>V</u> <u>I</u> <u>K</u> <u>R</u> <u>D</u> <u>A</u> <u>L</u> <u>O</u> <u>K</u> <u>V</u> <u>L</u> <u>E</u> <u>F</u> <u>Y</u> <u>T</u> <u>A</u> <u>F</u> <u>S</u> <u>H</u> <u>S</u> <u>F</u> <u>S</u> R--- <u>N</u> <u>L</u> <u>I</u> <u>L</u> <u>T</u> <u>Y</u> <u>N</u> <u>L</u> <u>R</u> <u>K</u> <u>R</u> <u>I</u> <u>V</u> <u>F</u> R-----		681
elk1	<u>T</u> <u>V</u> <u>P</u> <u>Q</u> <u>A</u> <u>E</u> <u>P</u> <u>K</u> <u>G</u> <u>N</u> <u>S</u> <u>I</u> <u>K</u> <u>K</u> <u>R</u> <u>L</u> <u>P</u> <u>S</u> <u>I</u> <u>V</u> <u>E</u> <u>D</u> <u>E</u> <u>E</u> <u>E</u> <u>E</u> <u>E</u> <u>V</u> <u>E</u> <u>E</u> <u>E</u> <u>E</u> <u>T</u> <u>T</u> <u>S</u> <u>L</u> <u>S</u> <u>P</u> <u>I</u> <u>Y</u> <u>T</u> <u>R</u> <u>G</u> <u>S</u> <u>S</u> <u>V</u> <u>S</u> <u>H</u> <u>S</u>		739
erg1	----- <u>S</u> <u>P</u> <u>S</u> <u>S</u> <u>A</u> <u>E</u> <u>L</u> <u>E</u> <u>S</u> <u>G</u> <u>F</u> <u>N</u> <u>R</u> <u>Q</u> ----- <u>R</u> <u>K</u> <u>R</u> <u>K</u> <u>L</u> <u>S</u> <u>F</u> <u>R</u>		894
eag1	----- <u>K</u> <u>I</u> <u>S</u> <u>D</u> <u>V</u> <u>K</u> <u>R</u> <u>E</u> <u>E</u> <u>E</u> <u>R</u> <u>M</u> <u>K</u> ----- <u>R</u> <u>K</u> <u>N</u> <u>E</u> <u>A</u> <u>P</u> <u>L</u> <u>I</u>		703

Fig. 2 (Cont'd)

elk1	<u>KKTGSSKSYLGLSLKQLTSGTVPFHSP</u> <u>IRVSSANS</u> <u>SPKTKQ</u> <u>EADPPNHGTR</u>	789
erg1	<u>RRTDKDTEQPG</u> <u>EV</u> <u>SALG</u> ----- <u>QGP</u> <u>ARVGP</u> <u>GP</u> <u>SCRG</u> - <u>QPGGPWG</u> <u>ESP</u> -	935
eag1	<u>LPPDHPVRR</u> <u>L</u> <u>FQRF</u> <u>Q</u> ----- <u>QKEAR</u> <u>LAAE</u> --- <u>RGGRD</u> <u>L</u> <u>DDLD</u> <u>VEK</u> -	741
elk1	<u>KEKNLKVQLCS</u> <u>LGTAGT</u> <u>PEL</u> <u>SPRIVD</u> <u>GIEDGNS</u> <u>SEETQ</u> <u>TDFG</u> <u>SEQIR</u> <u>PE</u>	839
erg1	----- <u>SSGP</u> <u>SSPES</u> ----- <u>SEDE</u> <u>GPGR</u> <u>SSSPLRL</u> <u>VPF</u>	962
eag1	----- <u>GNAL</u> <u>TDHTS</u> ----- <u>ANHSLV</u> <u>KASVVT</u> <u>TVRES</u> <u>PA</u>	768
elk1	<u>PRIS</u> <u>PSLGESE</u> <u>IGAAFL</u> <u>FIKAEET</u> <u>KQOINK</u> <u>LNSEVT</u> <u>TLTQ</u> <u>EVSQ</u> <u>LKGDMR</u>	889
erg1	<u>S</u> -- <u>SPRPPGD</u> <u>SP</u> <u>GGEP</u> <u>L</u> <u>TEDE</u> <u>GKSSD</u> <u>T</u> <u>CNPL</u> <u>SGAF</u> <u>SGVSN</u> - <u>IFS</u> <u>FWGDS</u> <u>R</u>	1009
eag1	<u>TPV</u> <u>SFQA</u> <u>AST</u> <u>STVSD</u> <u>HAKLHAP</u> - <u>GSECL</u> <u>GPKAGG</u> <u>GDPAK</u> <u>RKGW</u> <u>ARFKD</u> <u>AC</u>	817
elk1	<u>SI-MOL</u> <u>LENIL</u> <u>SPQOPS</u> <u>QFC</u> <u>SLHPTS</u> <u>ICPS</u> <u>RESFQ</u> <u>TRVSW</u> <u>SAHQ</u> <u>PCLHLQ</u>	938
erg1	<u>GRQYQ</u> <u>ELPRCP</u> <u>AP</u> ----- <u>APSL</u> <u>LNIP</u> <u>LSSPG</u> ----- <u>RRSR</u>	1039
eag1	<u>GK</u> -- <u>GEDWN</u> <u>KVSK</u> ----- <u>AESMET</u> <u>LP</u> <u>PERTKAS</u> <u>GEATL</u> <u>LKKT</u> <u>D</u>	851
elk1	<u>ANGA</u> <u>LYHGN</u> <u>VTSD</u> <u>IWSV</u> <u>DPS</u> <u>LVGS</u> <u>NPOR</u> <u>TEAHEQ</u> <u>SPVD</u> <u>SELH</u> <u>HSN</u> <u>LAY</u>	988
erg1	<u>GD</u> ----- <u>VESRL</u> <u>DALORQ</u> <u>DNRL</u> <u>ETRL</u> <u>SAD</u> - <u>MATV</u> <u>LQ</u> <u>LQ</u> <u>RM</u> <u>TLV</u> <u>P</u>	1079
eag1	<u>SC</u> ----- <u>DSG</u> <u>ITKSD</u> <u>LR</u> <u>LDNV</u> <u>GEAP</u> <u>SPQD</u> - <u>RSP</u> <u>ILAEV</u> <u>KHSFY</u> <u>PI</u> <u>P</u>	891
elk1	<u>SPSHCQ</u> <u>VIQ</u> <u>EGH</u> <u>LQFL</u> <u>R</u> <u>CISPH</u> <u>SDTT</u> <u>LTPL</u> <u>Q</u> <u>S</u> <u>ISAT</u> <u>LSSSV</u> <u>CS</u> <u>SSET</u> <u>SLH</u>	1038
erg1	<u>PAYS</u> <u>AVT</u> <u>TPG</u> ----- <u>PGPT</u> <u>ST</u> <u>SP</u> <u>LLP</u> <u>VGP</u> <u>VPT</u> <u>LTLD</u> <u>SLSQ</u> <u>V</u> <u>SQF</u>	1118
eag1	<u>EQT</u> <u>LQAT</u> <u>VLE</u> ----- <u>VKHEL</u> <u>KED</u> <u>I</u> <u>KALNA</u> <u>KMTS</u> <u>IEKQ</u> <u>LSE</u> <u>ILRI</u>	930
elk1	<u>LVLPSR</u> <u>SEEGS</u> <u>ITHG</u> <u>PVSS</u> <u>FS</u> <u>LENL</u> <u>PGS</u> <u>WD</u> <u>REGMMS</u> <u>ASTE</u> <u>PLEN</u> <u>F</u> <u>P</u> <u>VEV</u>	1088
erg1	<u>VAFEEL</u> - <u>PAGA</u> <u>PEL</u> <u>QD</u> <u>GP</u> <u>TRRL</u> <u>SL</u> <u>PG</u> <u>QLG</u> ----- <u>ALT</u> <u>SQ</u> <u>PL</u> <u>HRH</u> <u>GSD</u> <u>PG</u>	1162
eag1	<u>LMSR</u> ----- <u>GSSQ</u> <u>SQD</u> -- <u>ICEV</u> <u>SRP</u> -- <u>Q</u> ----- <u>S</u> - <u>PESDR</u> <u>DIFGA</u>	961
elk1	<u>TSTADV</u> <u>KDSKAINV</u>	1102
erg1	<u>S</u> -----	1163
eag1	<u>S</u> -----	962

Key: elk1 (SEQ ID NO:2)
 erg1 (SEQ ID NO:15)
 eag1 (SEQ ID NO:16)

Fig 3

CGGGATCCTT	GTGGACAAAC	TTTGATGGGG	AATTTACACAC	40
AGCGCTGGAA	AAATGCCGGT	TATGAAAGGA	TTGCTGGCGC	80
CACAGAACAC	CTTCCTGGAC	ACTATTGCCA	CCCGTTTCGA	120
CGGAACACAT	AGCAACTTCA	TCCTGGCCAA	TGCCCCAAGTG	160
GCAAAAGGTT	TCCCCATAGT	CTACTGTTCA	GATGGCTTCT	200
GTGAGCTGGC	TGGGTTTGCT	CGAACTGAAG	TCATGCAGAA	240
GAGTTGCAGC	TGCAAGTTTC	TGTTTGGGGT	GGAGACCAAC	280
GAGCAGCTGA	TGCTTCAGAT	CGAAAAGTCC	CTGGAGGAGA	320
AGGTAGAGTT	CAAAGGAGAA	ATTATGTTCT	ACAAGAAGAA	360
TGGGGCTCCA	TTTTGGTGCC	TGTTGGATAT	CGTTCCTATA	400
AAGAATGAGA	AAGGAGATGT	GGTCCTTTTC	CTGGCCTCAT	440
TCAAAGATAT	AACAGACACG	AAAGTGAAGA	TTACTTCAGA	480
AGATAAAAAA	GAAGACAGAG	CCAAAGGAAG	ATCAAGAGCA	520
GGGAGCCACT	TCGACTCAGC	CCGCAGACGG	AGCCGAGCAG	560
TCCTTTTATCA	CATCTCAGGA	CACCTGCAAA	GAAGAGAAAA	600
GAACAAATTG	AAAATAAATA	ATAACGTGTT	TGTAGATAAA	640
CCGGCGTTTC	CAGAGTATAA	GGTTTCCGAT	GCAAAAAAGT	680
CCAAGTTCAT	CCTGCTGCAC	TTCAGCACTT	TTAAAGCTGG	720
CTGGGACTGG	CTCATTTTGC	TGGCAACGTT	TTATGTTGCT	760
GTGACAGTCC	CTTACAACGT	GTGCTTCATT	GGCAATGAGG	800
ATCTGTCCAC	AACTCGGAGC	ACAACGGTCA	GTGACATCGC	840
TGTGGAGATT	CTCTTCATTA	TAGATATTAT	TCTAAATTTT	880
CGAACAACCT	ATGTCAGCAA	GTCTGGCCAA	GTTATCTTTG	920
AAGCGAGATC	CATTTGCATC	CACTACGTCA	CCACCTGGTT	960
CATCATTGAT	CTGATTGCTG	CCCTGCCCTT	TGACCTCCTG	1000
TATGCTTTCA	ATGTCACAGT	GGTGTCCCTC	GTACATCTTC	1040
TGAAGACTGT	TCGGCTGCTC	CGTCTTTTGC	GCCTCCTGCA	1080
GAAGCTGGAC	CGTTATTCTC	AGCACAGCAC	AATTGTCCTC	1120
ACCCTGCTCA	TGTCCATGTT	TGCTCTCCTT	GCACACTGGA	1160
TGGCATGTAT	CTGGTATGTC	ATTGGAAAAA	TGGAGAGGGA	1200
GGACAACAGC	CTTCTCAAGT	GGGAAGTCGG	TTGGCTTCAC	1240
GAGCTGGGAA	AGAGACTGGA	ATCTCCGTAC	TACGGCAACA	1280

Fig. 3 (Cont'd)

ACACGCTGGG	CGGCCCCGTCC	ATCCGCAGTG	CCTATATCGC	1320
AGCCTTGTAC	TTCACCTCTCA	GCAGCCTCAC	CAGCGTGGGA	1360
TTTGGGAATG	TGTCCGCTAA	CACGGATGCA	GAGAAGATCT	1400
TCTCCATCTG	TACCATGTTG	ATTGGAGCCC	TGATGCATGC	1440
CTTGGTATTT	GGGAATGTGA	CTGCCATCAT	ACAGAGAATG	1480
TACTCTAGAT	GGAGCCTGTA	CCATACTAGA	ACCAAGGACC	1520
TAAAGGACTT	CATCCGTGTG	CATCACCTGC	CCCAGCAACT	1560
CAAGCAGAGG	ATGCTTGAGT	ACTTTCAGAC	AACTTGGTCT	1600
GTCAACAATG	GAATAGATTC	AAATGAGCTT	TTGAAAGACT	1640
TTCCAGATGA	GCTGCGCTCT	GACATCACAA	TGCATCTGAA	1680
CAAGGAGATC	TTACAGCTGT	CCCTGTTTGA	ATGTGCTAGC	1720
CGGGGCTGCC	TCAGGTCTCT	GTCTCTCCAT	ATTAAAACCT	1760
CATTCTGTGC	CCCAGGAGAG	TATCTGCTGC	GCCAGGGAGA	1800
TGCGTTGCAG	GCCATCTACT	TCGTGTGCTC	AGGCTCTATG	1840
GAGGTTCTTA	AAGACAGCAT	GGTGTGCTG	ATTCTAGGGA	1880
AGGGGGATTT	AATTGGAGCA	AATTTATCAA	TTAAAGACCA	1920
AGTGATCAAG	ACCAACGCTG	ACGTGAAGGC	TCTGACCTAC	1960
TGTGATCTAC	AGTGCATCAT	CCTGAAAGGT	CTCTTTGAGG	2000
TGCTGGGCCT	TTACCCAGAG	TACGCACACA	AATTCGTAGA	2040
AGACATCCGC	ACGACCTCAC	ATACAACCTT	CGAGAAGGTC	2080
ATGAGAGTGA	TGTAATATCA	AGATTATCGA	ACAAATCTAC	2120
AGTCCCACAG	GCAGAGCCCA	AGGGGAATGG	AAGCATCAAG	2160
AAGAGACTCC	CATCCATTGT	GGAAGATGAG	GAAGAGGAGG	2200
AAGTGGAGGA	AGAGGAGACC	ACCTCCCTTT	CTCCCATCTA	2240
CACAAGGGGA	TCCTCTGTTT	CACACAGCAA	AAAGACTGGA	2280
AGCAGTAAGA	GCTATCTAGG	TTTGAGCTTA	AAGCAACTGA	2320
CCTCAGGAAC	AGTTCCATTC	CACTCACCTA	TCAGAGTCTC	2360
CAGTGCCAAC	TCCCCTAAAA	CCAAGCAGGA	AGCTGACCCA	2400
CCTAACCATG	GCACACGGAA	AGAGAAGAAT	CTGAAAGTTC	2440
AGCTCTGCAG	CCTGGGTACT	GCTGGAACCC	CAGAGCTCAG	2480
TCCGAGGATT	GTCGATGGAA	TTGAAGATGG	CAACAGCAGT	2520
GAGGAAACTC	AGACTTTTGA	TTTTGGCTCT	GAACAAATCA	2560

Fig. 3 (Cont'd)

GGCCAGAGCC	CAGGATTTCC	CCTTCCCTTG	GAGAATCAGA	2600
GATTGGAGCT	GCGTTTCTGT	TCATCAAGGC	TGAAGAAACC	2640
AAGCAGCAGA	TAAACAAGCT	CAACAGTGAG	GTCACAACAT	2680
TGACTCAGGA	GGTCTCCCAG	CTAGGGAAAG	ATATGAGAAG	2720
CATCATGCAA	CTTCTGGAAA	ACATCTTGTC	ACCTCAGCAG	2760
CCATCACAAT	TTTGTCTCTCT	GCATCCCCT	TCAATCTGTC	2800
CTTCCAGAGA	AAGTTTCCAG	ACTAGGGTGA	GCTGGAGTGC	2840
TCACCAGCCT	TGCCTACACT	TGCAGGCAA	TGGAGCACAT	2880
CTTTACCATG	GCAATGTCAC	CTCTGACATC	TGGAGTGTCG	2920
ACCCCTCCTT	GGTGGGCAGC	AACCCTCAAC	GAACTGAAGC	2960
TCATGAGCAA	AGTCCAGTAG	ATAGTGAAC	GCATCATTTCT	3000
CCAAACCTGG	CTTATTCCCC	CTCTCACTGC	CAGGTTATCC	3040
AAGAAGGCCA	CTTGCAAGTTC	CTAAGGTGCA	TCTCCCCTCA	3080
TTCAGATACC	ACACTGACAC	CTTTGCAGTC	CATCTCAGCC	3120
ACTCTCTCAT	CCTCTGTGTG	CTCCTCATCA	GAAACATCCT	3160
TGCACCTCGT	TCTCCCAAGT	AGGTCAGAGG	AGGGCAGCAT	3200
CACTCATGGA	CCTGTGAGTT	CTTTCAGTTT	GGAAAACCTTA	3240
CCAGGATCTT	GGGACCGAGA	AGGAATGATG	TCAGCCTCTA	3280
CAGAACCCTT	GGAGAACTTT	CCAGTAGAAG	TTGTCACAAG	3320
CACAGCGGAT	GTAAAAGACA	GCAAAGCCAT	AAACGTATAA	3360
TATCAGCACA	TAAGGGCAGC	TTTCAATGCC	AAATCCACTG	3400
CTGCATGACA	GCTCTAGTTT	GCCTTTGTGG	CTTCTAGCAG	3440
GTGTGGAGCC	TGAGCAAAGT	TAGGAATTCT	GCAGGAAAGA	3480
GGGCAAGGGG	CCAGTAAAAG	GCAGAGCCAC	CTCTATACTG	3520
TAGCAAACAA	TTTCTAGATC	GTAAGAGCAT	AAAACCTTTT	3560
CTGTACAGGT	ATTAACCTTAC	TGGTCTGATT	GACAGACTTT	3600
GGTAACAATC	CTATGACCCA	GAGGGTCTGA	GCAGATAGAA	3640
ACCCAGACA	AAGAGTTTGG	GGATTAGTTT	TGTCATAAGT	3680
GGATTTTTTT	GTGAAGTGCA	GCAAAGGTTT	TTTTTCCTGA	3720
GTGCCTGGTT	GTCATTCCTG	AA		3922










Fig. 4A - 4H

Fig 5A-5B

A



B



SEQUENCE LISTING

<110> DIXON, JANE
MCKINNON, DAVID

<120> Mammalian elk Potassium Channel Genes

<130> 08874138PC1

<140>

<141>

<160> 16

<170> PatentIn Ver. 2.1

<210> 1

<211> 3742

<212> DNA

<213> RAT

<220>

<223> elk1

<400> 1

```
cgggatcctt gtggacaaac tttgatgggg aatttcacac agcgcctggaa aaatgccggt 60
tatgaaagga ttgctggcgc cacagaacac ctctctggac actattgccca cccgtttcga 120
cggaacacat agcaacttca tcctggccaa tgcccaagtg gcaaaaagggt tccccatagt 180
ctactgttca gatggcttct gtgagctggc tgggtttgct cgaactgaag tcatgcagaa 240
gagttgcagc tgcaagtttc tgtttggggg ggagaccaac gagcagctga tgcttcagat 300
cgaaaagtcc ctggaggaga aggtagagtt caaaggagaa attatgttct acaagaagaa 360
tggggctcca ttttggtgcc tgttgatat cgttcctata aagaatgaga aaggagatgt 420
ggtccttttc ctggcctcat tcaaagatat aacagacacg aaagtgaaga ttacttcaga 480
agataaaaaa gaagacagag ccaaaggaag atcaagagca gggagccact tcgactcagc 540
ccgcagacgg agccgagcag tcctttatca catctcagga cacctgcaaa gaagagaaaa 600
gaacaaattg aaaataaata ataacgtgtt tgtagataaa ccggcgtttc cagagtataa 660
ggtttccgat gcaaaaaagt ccaagttcat cctgctgcac ttcagcactt ttaaagctgg 720
ctgggactgg ctcattttgc tggcaacggt ttatgttgct gtgacagtcc cttacaacgt 780
gtgcttcatt ggcaatgagg atctgtccac aactcggagc acaacggtca gtgacatcgc 840
tgtggagatt ctcttcatta tagatattat tctaaatttc cgaacaactt atgtcagcaa 900
gtctggccaa gttatctttg aagcgagatc catttgcatc cactacgtca ccacctgggt 960
catcattgat ctgattgctg ccctgccctt tgacctoctg tatgctttca atgtcacagt 1020
ggtgtccctc gtacatcttc tgaagactgt tcggctgctc cgtcttttgc gcctcctgca 1080
gaagctggac cgttattctc agcacagcac aattgtcctc accctgctca tgtccatgtt 1140
tgctctcctt gcacactgga tggcatgtat ctggatatgtc attggaaaaa tggagaggga 1200
ggacaacagc cttctcaagt ggggaagtcgg ttggcttcac gagctgggaa agagactgga 1260
atctccgtac tacggcaaca acacgctggg cggcccgtcc atccgcagtg cctatatcgc 1320
agccttgtac ttcactctca gcagcctcac cagcgtggga tttgggaatg tgtccgctaa 1380
```



```

cacggatgca gagaagatct tctccatctg taccatgttg attggagccc tgatgcatgc 1440
cttgggtatTTT ggggaatgtga ctgccatcat acagagaatg tactctagat ggagcctgta 1500
ccatactaga accaaggacc taaaggactt catccgtgtg catcacctgc cccagcaact 1560
caagcagagg atgcttgagt actttcagac aacttggtct gtcaacaatg gaatagattc 1620
aaatgagctt ttgaaagact ttccagatga gctgcgctct gacatcaca tgcattctgaa 1680
caaggagatc ttacagctgt ccctgtttga atgtgctagc cggggctgcc tcaggctctct 1740
gtctctccat attaaaacct cattctgtgc cccaggagag tatctgctgc gccagggaga 1800
tgcgttgcat gccatctact tcgtgtgctc aggtctctat gaggttctta aagacagcat 1860
gggtgttggt attctaggga agggggattt aattggagca aatttatcaa ttaaagacca 1920
agtgatcaag accaacgctg acgtgaaggc tctgacctac tgtgatctac agtgcattcat 1980
cctgaaagggt ctctttgagg tgctgggcct ttaccagag tacgcacaca aattcgtaga 2040
agacatccgc acgacctcac atacaacctt cgagaaggct atgagagtga tgtaatatca 2100
agattatcga acaaactctac agtcccacag gcagagccca aggggaatgg aagcatcaag 2160
aagagactcc catccattgt ggaagatgag gaagaggagg aagtggagga agaggagacc 2220
acctcccttt ctcccatcta cacaaggga tctctgttt cacacagcaa aaagactgga 2280
agcagtaaga gctatctagg tttgagctta aagcaactga cctcaggaac agttccattc 2340
cactcaccta tcagagtctc cagtccaac tcccctaaaa ccaagcagga agctgacca 2400
cctaaccatg gcacacggaa agagaagaat ctgaaagttc agctctgcag cctgggtact 2460
gctggaaccc cagagctcag tccgaggatt gtcgatggaa ttgaagatgg caacagcagt 2520
gaggaaactc agacttttga ttttggtctt gaacaaatca ggccagagcc caggatttcc 2580
ccttcccttg gagaatcaga gattggagct gcgtttctgt tcatcaaggc tgaagaaacc 2640
aagcagcaga taaacaagct caacagttag gtcacaacat tgactcagga ggtctcccag 2700
ctagggaaag atatgagaag catcatgcaa cttctggaaa acatcttgtc acctcagcag 2760
ccatcacaat tttgttctct gcatccact tcaatctgtc cttccagaga aagtttccag 2820
actagggtga gctggagtgc tcaccagcct tgccctacact tgcaggcaaa tggagcacat 2880
ctttaccatg gcaatgtcac ctctgacatc tggagtgtcg acccctcctt ggtgggcagc 2940
aacctcaac gaactgaagc tcatgagcaa agtccagtag atagtgaact gcattattct 3000
ccaaacctgg cttattcccc ctctcactgc caggttatcc aagaaggcca cttgcagttc 3060
ctaagggtga tctccctca ttcagatacc aactgacac ctttgagtc catctcagcc 3120
actctctcat cctctgtgtg ctctcatca gaaacatcct tgcacctcgt tctcccaagt 3180
aggtcagagg agggcagcat cactcatgga cctgtgagtt ctttcagttt ggaaaactta 3240
ccaggatctt gggaccgaga aggaatgatg tcagcctcta cagaaccctt ggagaacttt 3300
ccagtagaag ttgtcacaag cacagcggat gtaaaagaca gcaaagccat aaacgtataa 3360
tatcagcaca taagggcagc tttcaatgcc aaatccactg ctgcatgaca gctctagttt 3420
gcctttgtgg cttctagcag gtgtggagcc tgagcaaagt taggaattct gcaggaaaga 3480
gggcaagggg ccagtaaaag gcagagccac ctctatactg tagcaaaca tttctagatc 3540
gtagaagcat aaaacctttt ctgtacaggt attaaacttac tggctctgatt gacagacttt 3600
ggtaacaatc ctatgaccca gagggctctga gcagatagaa accccagaca aagagtttgg 3660
ggattagttt tgtcataagt ggattttttt gtgaagtgca gcaaagggtt ttttctctga 3720
gtgcctggtt gtcattctct aa 3742

```

<210> 2

<211> 1102

<212> PRT

<213> RAT

<220>

<223> elk1

<400> 2

```

Met Pro Val Met Lys Gly Leu Leu Ala Pro Gln Asn Thr Phe Leu Asp
 1             5             10             15

Thr Ile Ala Thr Arg Phe Asp Gly Thr His Ser Asn Phe Ile Leu Ala
      20             25             30

Asn Ala Gln Val Ala Lys Gly Phe Pro Ile Val Tyr Cys Ser Asp Gly
      35             40             45

Phe Cys Glu Leu Ala Gly Phe Ala Arg Thr Glu Val Met Gln Lys Ser
      50             55             60

Cys Ser Cys Lys Phe Leu Phe Gly Val Glu Thr Asn Glu Gln Leu Met
      65             70             75             80

Leu Gln Ile Glu Lys Ser Leu Glu Glu Lys Val Glu Phe Lys Gly Glu
      85             90             95

Ile Met Phe Tyr Lys Lys Asn Gly Ala Pro Phe Trp Cys Leu Leu Asp
      100            105            110

Ile Val Pro Ile Lys Asn Glu Lys Gly Asp Val Val Leu Phe Leu Ala
      115            120            125

Ser Phe Lys Asp Ile Thr Asp Thr Lys Val Lys Ile Thr Ser Glu Asp
      130            135            140

Lys Lys Glu Asp Arg Ala Lys Gly Arg Ser Arg Ala Gly Ser His Phe
      145            150            155            160

Asp Ser Ala Arg Arg Arg Ser Arg Ala Val Leu Tyr His Ile Ser Gly
      165            170            175

His Leu Gln Arg Arg Glu Lys Asn Lys Leu Lys Ile Asn Asn Asn Val
      180            185            190

Phe Val Asp Lys Pro Ala Phe Pro Glu Tyr Lys Val Ser Asp Ala Lys
      195            200            205

Lys Ser Lys Phe Ile Leu Leu His Phe Ser Thr Phe Lys Ala Gly Trp
      210            215            220

Asp Trp Leu Ile Leu Leu Ala Thr Phe Tyr Val Ala Val Thr Val Pro
      225            230            235            240

```

Tyr Asn Val Cys Phe Ile Gly Asn Glu Asp Leu Ser Thr Thr Arg Ser
 245 250 255

Thr Thr Val Ser Asp Ile Ala Val Glu Ile Leu Phe Ile Ile Asp Ile
 260 265 270

Ile Leu Asn Phe Arg Thr Thr Tyr Val Ser Lys Ser Gly Gln Val Ile
 275 280 285

Phe Glu Ala Arg Ser Ile Cys Ile His Tyr Val Thr Thr Trp Phe Ile
 290 295 300

Ile Asp Leu Ile Ala Ala Leu Pro Phe Asp Leu Leu Tyr Ala Phe Asn
 305 310 315 320

Val Thr Val Val Ser Leu Val His Leu Leu Lys Thr Val Arg Leu Leu
 325 330 335

Arg Leu Leu Arg Leu Leu Gln Lys Leu Asp Arg Tyr Ser Gln His Ser
 340 345 350

Thr Ile Val Leu Thr Leu Leu Met Ser Met Phe Ala Leu Leu Ala His
 355 360 365

Trp Met Ala Cys Ile Trp Tyr Val Ile Gly Lys Met Glu Arg Glu Asp
 370 375 380

Asn Ser Leu Leu Lys Trp Glu Val Gly Trp Leu His Glu Leu Gly Lys
 385 390 395 400

Arg Leu Glu Ser Pro Tyr Tyr Gly Asn Asn Thr Leu Gly Gly Pro Ser
 405 410 415

Ile Arg Ser Ala Tyr Ile Ala Ala Leu Tyr Phe Thr Leu Ser Ser Leu
 420 425 430

Thr Ser Val Gly Phe Gly Asn Val Ser Ala Asn Thr Asp Ala Glu Lys
 435 440 445

Ile Phe Ser Ile Cys Thr Met Leu Ile Gly Ala Leu Met His Ala Leu
 450 455 460

Val Phe Gly Asn Val Thr Ala Ile Ile Gln Arg Met Tyr Ser Arg Trp
 465 470 475 480

Ser Leu Tyr His Thr Arg Thr Lys Asp Leu Lys Asp Phe Ile Arg Val
 485 490 495

His His Leu Pro Gln Gln Leu Lys Gln Arg Met Leu Glu Tyr Phe Gln
 500 505 510

Thr Thr Trp Ser Val Asn Asn Gly Ile Asp Ser Asn Glu Leu Leu Lys
 515 520 525

Asp Phe Pro Asp Glu Leu Arg Ser Asp Ile Thr Met His Leu Asn Lys
 530 535 540

Glu Ile Leu Gln Leu Ser Leu Phe Glu Cys Ala Ser Arg Gly Cys Leu
 545 550 555 560

Arg Ser Leu Ser Leu His Ile Lys Thr Ser Phe Cys Ala Pro Gly Glu
 565 570 575

Tyr Leu Leu Arg Gln Gly Asp Ala Leu Gln Ala Ile Tyr Phe Val Cys
 580 585 590

Ser Gly Ser Met Glu Val Leu Lys Asp Ser Met Val Leu Ala Ile Leu
 595 600 605

Gly Lys Gly Asp Leu Ile Gly Ala Asn Leu Ser Ile Lys Asp Gln Val
 610 615 620

Ile Lys Thr Asn Ala Asp Val Lys Ala Leu Thr Tyr Cys Asp Leu Gln
 625 630 635 640

Cys Ile Ile Leu Lys Gly Leu Phe Glu Val Leu Gly Leu Tyr Pro Glu
 645 650 655

Tyr Ala His Lys Phe Val Glu Asp Ile Gln His Asp Leu Thr Tyr Asn
 660 665 670

Leu Arg Glu Gly His Glu Ser Asp Val Ile Ser Arg Leu Ser Asn Lys
 675 680 685

Ser Thr Val Pro Gln Ala Glu Pro Lys Gly Asn Gly Ser Ile Lys Lys
 690 695 700

Arg Leu Pro Ser Ile Val Glu Asp Glu Glu Glu Glu Glu Val Glu Glu
 705 710 715 720

Glu Glu Thr Thr Ser Leu Ser Pro Ile Tyr Thr Arg Gly Ser Ser Val
 725 730 735

Ser His Ser Lys Lys Thr Gly Ser Ser Lys Ser Tyr Leu Gly Leu Ser
 740 745 750

Leu Lys Gln Leu Thr Ser Gly Thr Val Pro Phe His Ser Pro Ile Arg
 755 760 765

Val Ser Ser Ala Asn Ser Pro Lys Thr Lys Gln Glu Ala Asp Pro Pro
 770 775 780

Asn His Gly Thr Arg Lys Glu Lys Asn Leu Lys Val Gln Leu Cys Ser
 785 790 795 800

Leu Gly Thr Ala Gly Thr Pro Glu Leu Ser Pro Arg Ile Val Asp Gly
 805 810 815

Ile Glu Asp Gly Asn Ser Ser Glu Glu Thr Gln Thr Phe Asp Phe Gly
 820 825 830

Ser Glu Gln Ile Arg Pro Glu Pro Arg Ile Ser Pro Ser Leu Gly Glu
 835 840 845

Ser Glu Ile Gly Ala Ala Phe Leu Phe Ile Lys Ala Glu Glu Thr Lys
 850 855 860

Gln Gln Ile Asn Lys Leu Asn Ser Glu Val Thr Thr Leu Thr Gln Glu
 865 870 875 880

Val Ser Gln Leu Gly Lys Asp Met Arg Ser Ile Met Gln Leu Leu Glu
 885 890 895

Asn Ile Leu Ser Pro Gln Gln Pro Ser Gln Phe Cys Ser Leu His Pro
 900 905 910

Thr Ser Ile Cys Pro Ser Arg Glu Ser Phe Gln Thr Arg Val Ser Trp
 915 920 925

Ser Ala His Gln Pro Cys Leu His Leu Gln Ala Asn Gly Ala His Leu
 930 935 940

Tyr His Gly Asn Val Thr Ser Asp Ile Trp Ser Val Asp Pro Ser Leu
 945 950 955 960

Val Gly Ser Asn Pro Gln Arg Thr Glu Ala His Glu Gln Ser Pro Val
 965 970 975

Asp Ser Glu Leu His His Ser Pro Asn Leu Ala Tyr Ser Pro Ser His
 980 985 990

Cys Gln Val Ile Gln Glu Gly His Leu Gln Phe Leu Arg Cys Ile Ser
 995 1000 1005

Pro His Ser Asp Thr Thr Leu Thr Pro Leu Gln Ser Ile Ser Ala Thr
 1010 1015 1020

Leu Ser Ser Ser Val Cys Ser Ser Ser Glu Thr Ser Leu His Leu Val
 1025 1030 1035 1040

Leu Pro Ser Arg Ser Glu Glu Gly Ser Ile Thr His Gly Pro Val Ser
 1045 1050 1055

Ser Phe Ser Leu Glu Asn Leu Pro Gly Ser Trp Asp Arg Glu Gly Met
 1060 1065 1070

Met Ser Ala Ser Thr Glu Pro Leu Glu Asn Phe Pro Val Glu Val Val
 1075 1080 1085

Thr Ser Thr Ala Asp Val Lys Asp Ser Lys Ala Ile Asn Val
 1090 1095 1100

<210> 3

<211> 154

<212> PRT

<213> RAT

<220>

<223> elk 2

<400> 3

Lys Gly Glu Val Ala Leu Phe Leu Val Ser His Lys Asp Ile Ser Glu
 1 5 10 15

Thr Lys Asn Arg Gly Gly Pro Asp Asn Trp Lys Glu Arg Gly Gly Gly
 20 25 30

Arg Arg Arg Tyr Gly Arg Ala Gly Ser Lys Gly Phe Asn Ala Asn Arg
 35 40 45

Arg Arg Ser Arg Ala Val Leu Tyr His Leu Ser Gly His Leu Gln Lys
 50 55 60

Gln Pro Lys Gly Lys His Lys Leu Asn Lys Gly Val Phe Gly Glu Lys
 65 70 75 80

Pro Asn Leu Pro Glu Tyr Lys Val Ala Ala Ile Arg Lys Ser Pro Phe
 85 90 95

Ile Leu Leu His Cys Gly Ala Leu Arg Ala Thr Trp Asp Gly Phe Ile
 100 105 110

Leu Leu Ala Thr Leu Tyr Val Ala Val Thr Val Pro Tyr Ser Val Cys
 115 120 125

Val Ser Thr Ala Arg Glu Pro Ser Ala Ala Arg Gly Pro Pro Ser Val
 130 135 140

Cys Asp Leu Ala Val Glu Val Leu Phe Ile
 145 150

<210> 4

<211> 141

<212> PRT

<213> RAT

<220>

<223> eag 2

<400> 4

Val Ile Leu Ile Leu Thr Phe Tyr Thr Ala Ile Met Val Pro Tyr Asn
 1 5 10 15

Val Ser Phe Lys Thr Lys Gln Asn Asn Ile Ala Trp Leu Val Leu Asp
 20 25 30

Ser Val Val Asp Val Ile Phe Leu Val Asp Ile Val Leu Asn Phe His
 35 40 45

Thr Thr Phe Val Gly Pro Gly Gly Glu Val Ile Ser Asp Pro Lys Leu
 50 55 60

Ile Arg Met Asn Tyr Leu Lys Thr Trp Phe Val Ile Asp Leu Leu Ser
 65 70 75 80

Cys Leu Pro Tyr Asp Ile Ile Asn Ala Phe Glu Asn Val Asp Glu Gly
 85 90 95

Ile Ser Ser Leu Phe Ser Ser Leu Lys Val Val Arg Leu Leu Arg Leu
 100 105 110

Gly Arg Val Ala Arg Lys Leu Asp His Tyr Leu Glu Tyr Gly Ala Ala
 115 120 125

Val Leu Val Leu Leu Val Cys Val Phe Gly Leu Val Ala
 130 135 140

<210> 5
<211> 21
<212> DNA
<213> RAT

<220>
<223> eag

<400> 5
ttyaarrcnr yntgggaytg g

21

<210> 6
<211> 24
<212> DNA
<213> RAT

<220>
<223> eag

<400> 6
rtaccadatr cangcnagcc artg

24

<210> 7
<211> 20
<212> DNA
<213> RAT

<220>
<223> eag

<400> 7
cgggatcctt gtggacaaac

20

<210> 8
<211> 20
<212> DNA
<213> RAT

<220>
<223> eag

<400> 8
cggaccaaca gtaaggactt

20

<210> 9
<211> 21
<212> DNA
<213> RAT

<220>
<223> eag

<400> 9
gtgataccca taaagaatga g

21

<210> 10
<211> 17
<212> DNA
<213> RAT

<220>
<223> eag

<400> 10
ctgtaacacg acttaaa

17

<210> 11
<211> 17
<212> DNA
<213> RAT

<220>
<223> eag

<400> 11
tgctgcggtg agacacg

17

<210> 12
<211> 19
<212> DNA
<213> RAT

<220>
<223> eag

<400> 12
gcgtgggttg tgtactggt

19

<210> 13
 <211> 464
 <212> DNA
 <213> RAT

<220>
 <223> elk 2

<400> 13
 aagggggagg tggccctctt cctggtctct cacaaggaca tcagtgagac caagaaccga 60
 ggaggccctg acaactggaa ggagagaggt ggtggccgac gcagatatgg tcgggcagga 120
 tccaaaggct ttaatgccaa tcggaggcgc agccgggagg ttctctacca cctctctggt 180
 cacctgcaga aacaacccaa gggcaagcac aaactcaata aggggtgtgtt tggagagaag 240
 ccaaatttgc ccgaatataa agtcgctgct atccggaagt caccctttat cctgctgcac 300
 tgtggggctc tgagagccac ctgggatggc ttcactctgc tcgccacgct ctacgtggct 360
 gtcactgtgc catacagcgt gtgtgtgagc acagcacggg agcccagtgc tgcccgtggc 420
 ccacctagtg tctgtgacct ggccgtggaa gtccctcttca tctt 464

<210> 14
 <211> 423
 <212> DNA
 <213> RAT

<220>
 <223> eag 2

<400> 14
 gtgatttttaa ttcttacctt ctacaccgcc atcatgggttc cttacaacgt ttccttcaaa 60
 acaaaacaga acaatatcgc ctggctgggt ctggacagcg tggaggacgt tatttttctg 120
 gtggacatcg ttttaacctt tcacacgact tttgtggggc cgggtggaga ggcatatttct 180
 gacccaaaac tcatacggat gaactatctg aaaacttggg ttgtgattga tctgctgtct 240
 tgtttacctt atgacatcat caatgccttt gaaaatgtgg atgagggaat cagcagtctc 300
 ttcagctctt taaaggtggg acgcctctta cgcctgggcc gtgttgctag gaaactggac 360
 cattacctgg aatatggagc agcggtcctt gtgctcctgg tatgtgtgtt tggactgggt 420
 gcc 423

<210> 15
 <211> 1163
 <212> PRT
 <213> RAT

<220>
 <223> erg 1

<400> 15
 Met Pro Val Arg Arg Gly His Val Ala Pro Gln Asn Thr Phe Leu Asp

12

260	265	270
Arg Ser Arg Glu Ser Cys Ala Ser Val Arg Arg Ala Ser Ser Ala Asp		
275	280	285
Asp Ile Glu Ala Met Arg Ala Gly Ala Leu Pro Leu Pro Pro Arg His		
290	295	300
Ala Ser Thr Gly Ala Met His Pro Leu Arg Ser Gly Leu Leu Asn Ser		
305	310	315
Thr Ser Asp Ser Asp Leu Val Arg Tyr Arg Thr Ile Ser Lys Ile Pro		
325	330	335
Gln Ile Thr Leu Asn Phe Val Asp Leu Lys Gly Asp Pro Phe Leu Ala		
340	345	350
Ser Pro Thr Ser Asp Arg Glu Ile Ile Ala Pro Lys Ile Lys Glu Arg		
355	360	365
Thr His Asn Val Thr Glu Lys Val Thr Gln Val Leu Ser Leu Gly Ala		
370	375	380
Asp Val Leu Pro Glu Tyr Lys Leu Gln Ala Pro Arg Ile His Arg Trp		
385	390	395
Thr Ile Leu His Tyr Ser Pro Phe Lys Ala Val Trp Asp Trp Leu Ile		
405	410	415
Leu Leu Leu Val Ile Tyr Thr Ala Val Phe Thr Pro Tyr Ser Ala Ala		
420	425	430
Phe Leu Leu Lys Glu Thr Glu Asp Gly Ser Gln Ala Pro Asp Cys Gly		
435	440	445
Tyr Ala Cys Gln Pro Leu Ala Val Val Asp Leu Leu Val Asp Ile Met		
450	455	460
Phe Ile Val Asp Ile Leu Ile Asn Phe Arg Thr Thr Tyr Val Asn Ala		
465	470	475
Asn Glu Glu Val Val Ser His Pro Gly Arg Ile Ala Val His Tyr Phe		
485	490	495
Lys Gly Trp Phe Leu Ile Asp Met Val Ala Ala Ile Pro Phe Asp Leu		
500	505	510
Leu Ile Phe Gly Ser Gly Ser Glu Glu Leu Ile Gly Leu Leu Lys Thr		

515	520	525
Ala Arg Leu Leu Arg Leu Val Arg Val Ala Arg Lys Leu Asp Arg Tyr		
530	535	540
Ser Glu Tyr Gly Ala Ala Val Leu Phe Leu Leu Met Cys Thr Phe Ala		
545	550	555 560
Leu Ile Ala His Trp Leu Ala Cys Ile Trp Tyr Ala Ile Gly Asn Met		
	565	570 575
Glu Gln Pro His Met Asp Ser His Ile Gly Trp Leu His Asn Leu Gly		
	580	585 590
Asp Gln Ile Gly Lys Pro Tyr Asn Ser Ser Gly Leu Gly Gly Pro Ser		
	595	600 605
Ile Lys Asp Lys Tyr Val Thr Ala Leu Tyr Phe Thr Phe Ser Ser Leu		
	610	615 620
Thr Ser Val Gly Phe Gly Asn Val Ser Pro Asn Thr Asn Ser Glu Lys		
	625	630 635 640
Ile Phe Ser Ile Cys Val Met Leu Ile Gly Ser Leu Met Tyr Ala Ser		
	645	650 655
Ile Phe Gly Asn Val Ser Ala Ile Ile Gln Arg Leu Tyr Ser Gly Thr		
	660	665 670
Ala Arg Tyr His Thr Gln Met Leu Arg Val Arg Glu Phe Ile Arg Phe		
	675	680 685
His Gln Ile Pro Asn Pro Leu Arg Gln Arg Leu Glu Glu Tyr Phe Gln		
	690	695 700
His Ala Trp Ser Tyr Thr Asn Gly Ile Asp Met Asn Ala Val Leu Lys		
	705	710 715 720
Gly Phe Pro Glu Cys Leu Gln Ala Asp Ile Cys Leu His Leu Asn Arg		
	725	730 735
Ser Leu Leu Gln His Cys Lys Pro Phe Arg Gly Ala Thr Lys Gly Cys		
	740	745 750
Leu Arg Ala Leu Ala Met Lys Phe Lys Thr Thr His Ala Pro Pro Gly		
	755	760 765
Asp Thr Leu Val His Ala Gly Asp Leu Leu Thr Ala Leu Tyr Phe Ile		

770	775	780
Ser Arg Gly Ser Ile Glu Ile Leu Arg Gly Asp Val Val Val Ala Ile		
785	790	795 800
Leu Gly Lys Asn Asp Ile Phe Gly Glu Pro Leu Asn Leu Tyr Ala Arg		
	805	810 815
Pro Gly Lys Ser Asn Gly Asp Val Arg Ala Leu Thr Tyr Cys Asp Leu		
	820	825 830
His Lys Ile His Arg Asp Asp Leu Leu Glu Val Leu Asp Met Tyr Pro		
	835	840 845
Glu Phe Ser Asp His Phe Trp Ser Ser Leu Glu Ile Thr Phe Asn Leu		
	850	855 860
Arg Asp Thr Asn Met Ile Pro Gly Ser Pro Ser Ser Ala Glu Leu Glu		
	865	870 875 880
Ser Gly Phe Asn Arg Gln Arg Lys Arg Lys Leu Ser Phe Arg Arg Arg		
	885	890 895
Thr Asp Lys Asp Thr Glu Gln Pro Gly Glu Val Ser Ala Leu Gly Gln		
	900	905 910
Gly Pro Ala Arg Val Gly Pro Gly Pro Ser Cys Arg Gly Gln Pro Gly		
	915	920 925
Gly Pro Trp Gly Glu Ser Pro Ser Ser Gly Pro Ser Ser Pro Glu Ser		
	930	935 940
Ser Glu Asp Glu Gly Pro Gly Arg Ser Ser Ser Pro Leu Arg Leu Val		
	945	950 955 960
Pro Phe Ser Ser Pro Arg Pro Pro Gly Asp Ser Pro Gly Gly Glu Pro		
	965	970 975
Leu Thr Glu Asp Gly Glu Lys Ser Ser Asp Thr Cys Asn Pro Leu Ser		
	980	985 990
Gly Ala Phe Ser Gly Val Ser Asn Ile Phe Ser Phe Trp Gly Asp Ser		
	995	1000 1005
Arg Gly Arg Gln Tyr Gln Glu Leu Pro Arg Cys Pro Ala Pro Ala Pro		
	1010	1015 1020
Ser Leu Leu Asn Ile Pro Leu Ser Ser Pro Gly Arg Arg Ser Arg Gly		

1025 1030 1035 1040
 Asp Val Glu Ser Arg Leu Asp Ala Leu Gln Arg Gln Asp Asn Arg Leu
 1045 1050 1055
 Glu Thr Arg Leu Ser Ala Asp Met Ala Thr Val Leu Gln Leu Leu Gln
 1060 1065 1070
 Arg Gln Met Thr Leu Val Pro Pro Ala Tyr Ser Ala Val Thr Thr Pro
 1075 1080 1085
 Gly Pro Gly Pro Thr Ser Thr Ser Pro Leu Leu Pro Val Gly Pro Val
 1090 1095 1100
 Pro Thr Leu Thr Leu Asp Ser Leu Ser Gln Val Ser Gln Phe Val Ala
 1105 1110 1115 1120
 Phe Glu Glu Leu Pro Ala Gly Ala Pro Glu Leu Pro Gln Asp Gly Pro
 1125 1130 1135
 Thr Arg Arg Leu Ser Leu Pro Gly Gln Leu Gly Ala Leu Thr Ser Gln
 1140 1145 1150
 Pro Leu His Arg His Gly Ser Asp Pro Gly Ser
 1155 1160

 <210> 16
 <211> 962
 <212> PRT
 <213> RAT

 <220>
 <223> eag 1

 <400> 16
 Met Thr Met Ala Gly Gly Arg Arg Gly Leu Val Ala Pro Gln Asn Thr
 1 5 10 15
 Phe Leu Glu Asn Ile Val Arg Arg Ser Asn Asp Thr Asn Phe Val Leu
 20 25 30
 Gly Asn Ala Gln Ile Val Asp Trp Pro Ile Val Tyr Ser Asn Asp Gly
 35 40 45
 Phe Cys Lys Leu Ser Gly Tyr His Arg Ala Glu Val Met Gln Lys Ser
 50 55 60

Ser Ala Cys Ser Phe Met Tyr Gly Glu Leu Thr Asp Lys Asp Thr Val
 65 70 75 80
 Glu Lys Val Arg Gln Thr Phe Glu Asn Tyr Glu Met Asn Ser Phe Glu
 85 90 95
 Ile Leu Met Tyr Lys Lys Asn Arg Thr Pro Val Trp Phe Phe Val Lys
 100 105 110
 Ile Ala Pro Ile Arg Asn Glu Gln Asp Lys Val Val Leu Phe Leu Cys
 115 120 125
 Thr Phe Ser Asp Ile Thr Ala Phe Lys Gln Pro Ile Lys Asp Asp Ser
 130 135 140
 Cys Lys Gly Trp Gly Lys Phe Ala Arg Leu Thr Arg Ala Leu Thr Ser
 145 150 155 160
 Ser Arg Gly Val Leu Gln Gln Leu Ala Pro Ser Val Gln Lys Gly Glu
 165 170 175
 Asn Val His Lys His Ser Arg Leu Ala Glu Val Leu Gln Leu Gly Ser
 180 185 190
 Asp Ile Leu Pro Gln Tyr Lys Gln Glu Ala Pro Lys Pro Pro His Ile
 195 200 205
 Ile Leu His Tyr Cys Val Phe Lys Thr Thr Thr Trp Asp Trp Ile Ile
 210 215 220
 Leu Ile Leu Thr Phe Tyr Thr Ala Ile Leu Val Pro Tyr Asn Val Ser
 225 230 235 240
 Phe Lys Thr Arg Gln Asn Asn Val Ala Trp Leu Val Val Asp Ser Ile
 245 250 255
 Val Asp Val Ile Phe Leu Val Asp Ile Val Leu Asn Phe His Thr Thr
 260 265 270
 Phe Val Gly Pro Ala Gly Glu Val Ile Ser Asp Pro Lys Leu Ile Arg
 275 280 285
 Met Asn Tyr Leu Lys Thr Trp Phe Val Ile Asp Leu Leu Ser Cys Leu
 290 295 300
 Pro Tyr Asp Val Ile Asn Ala Phe Glu Asn Val Asp Glu Gly Ile Ser
 305 310 315 320

Ser Leu Phe Ser Ser Leu Lys Val Val Arg Leu Leu Arg Leu Gly Arg
 325 330 335
 Val Ala Arg Lys Leu Asp His Tyr Ile Glu Tyr Gly Ala Ala Val Leu
 340 345 350
 Val Leu Leu Val Cys Val Phe Gly Leu Ala Ala His Trp Met Ala Cys
 355 360 365
 Ile Trp Tyr Ser Ile Gly Asp Tyr Glu Ile Phe Asp Glu Asp Thr Lys
 370 375 380
 Thr Ile Arg Asn Asn Ser Trp Leu Tyr Gln Leu Ala Leu Asp Ile Gly
 385 390 395 400
 Thr Pro Tyr Gln Phe Asn Gly Ser Gly Ser Gly Lys Trp Glu Gly Gly
 405 410 415
 Pro Ser Lys Asn Ser Val Tyr Ile Ser Ser Leu Tyr Phe Thr Met Thr
 420 425 430
 Ser Leu Thr Ser Val Gly Phe Gly Asn Ile Ala Pro Ser Thr Asp Ile
 435 440 445
 Glu Lys Ile Phe Ala Val Ala Ile Met Met Ile Gly Ser Leu Leu Tyr
 450 455 460
 Ala Thr Ile Phe Gly Asn Val Thr Thr Ile Phe Gln Gln Met Tyr Ala
 465 470 475 480
 Asn Thr Asn Arg Tyr His Glu Met Leu Asn Ser Val Arg Asp Phe Leu
 485 490 495
 Lys Leu Tyr Gln Val Pro Lys Gly Leu Ser Glu Arg Val Met Asp Tyr
 500 505 510
 Ile Val Ser Thr Trp Ser Met Ser Arg Gly Ile Asp Thr Lys Lys Val
 515 520 525
 Leu Gln Ile Cys Pro Lys Asp Asn Arg Ala Asp Ile Cys Val His Leu
 530 535 540
 Asn Arg Lys Val Phe Lys Glu His Pro Ala Phe Arg Leu Ala Ser Asp
 545 550 555 560
 Gly Cys Leu Arg Ala Leu Ala Met Glu Phe Gln Thr Val His Cys Ala
 565 570 575

Pro Gly Asp Leu Ile Tyr His Ala Gly Glu Asp Val Asp Ser Leu Cys
580 585 590

Phe Val Val Ser Gly Ser Leu Glu Val Ile Gln Asp Asp Glu Val Val
595 600 605

Ala Ile Leu Gly Lys Gly Asp Val Phe Gly Asp Val Phe Trp Lys Glu
610 615 620

Ala Thr Leu Ala Gln Ser Cys Ala Asn Val Arg Ala Leu Thr Tyr Cys
625 630 635 640

Asp Leu His Val Ile Lys Arg Asp Ala Leu Gln Lys Val Leu Glu Phe
645 650 655

Tyr Thr Ala Phe Ser His Ser Phe Ser Arg Asn Leu Ile Leu Thr Tyr
660 665 670

Asn Leu Arg Lys Arg Ile Val Phe Arg Lys Ile Ser Asp Val Lys Arg
675 680 685

Glu Glu Glu Glu Arg Met Lys Arg Lys Asn Glu Ala Pro Leu Ile Leu
690 695 700

Pro Pro Asp His Pro Val Arg Arg Leu Phe Gln Arg Phe Arg Gln Gln
705 710 715 720

Lys Glu Ala Arg Leu Ala Ala Glu Arg Gly Gly Arg Asp Leu Asp Asp
725 730 735

Leu Asp Val Glu Lys Gly Asn Ala Leu Thr Asp His Thr Ser Ala Asn
740 745 750

His Ser Leu Val Lys Ala Ser Val Val Thr Val Arg Glu Ser Pro Ala
755 760 765

Thr Pro Val Ser Phe Gln Ala Ala Ser Thr Ser Thr Val Ser Asp His
770 775 780

Ala Lys Leu His Ala Pro Gly Ser Glu Cys Leu Gly Pro Lys Ala Gly
785 790 795 800

Gly Gly Asp Pro Ala Lys Arg Lys Gly Trp Ala Arg Phe Lys Asp Ala
805 810 815

Cys Gly Lys Gly Glu Asp Trp Asn Lys Val Ser Lys Ala Glu Ser Met
820 825 830

Glu Thr Leu Pro Glu Arg Thr Lys Ala Ser Gly Glu Ala Thr Leu Lys
835 840 845

Lys Thr Asp Ser Cys Asp Ser Gly Ile Thr Lys Ser Asp Leu Arg Leu
850 855 860

Asp Asn Val Gly Glu Ala Pro Ser Pro Gln Asp Arg Ser Pro Ile Leu
865 870 875 880

Ala Glu Val Lys His Ser Phe Tyr Pro Ile Pro Glu Gln Thr Leu Gln
885 890 895

Ala Thr Val Leu Glu Val Lys His Glu Leu Lys Glu Asp Ile Lys Ala
900 905 910

Leu Asn Ala Lys Met Thr Ser Ile Glu Lys Gln Leu Ser Glu Ile Leu
915 920 925

Arg Ile Leu Met Ser Arg Gly Ser Ser Gln Ser Pro Gln Asp Ile Cys
930 935 940

Glu Val Ser Arg Pro Gln Ser Pro Glu Ser Asp Arg Asp Ile Phe Gly
945 950 955 960

Ala Ser

INTERNATIONAL SEARCH REPORT

International application No.
US99/19902

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07K 14/00, 14/435; C12N 5/16, 15/12, 15/63; G01N 33/53, 33/566

US CL : 435/6, 7.2, 320.1, 325; 530/350; 536/23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 7.2, 320.1, 325; 530/350; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN, BIOSCIENCE, MEDLINE, BIOSIS, CAPLUS, GENESEQ, GENBANK, PIR

search terms: potassium channel, ether-a-go-go, eag, erg, elk

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- A	SHI et al. Identification of two nervous system-specific members of the <i>erg</i> potassium channel gene family. The Journal of Neuroscience. 15 December 1997, Vol. 17, No. 24, pages 9423-9432, especially pages 9423-9426 and figures 1-8.	1-10, 12-15, 17-22, 32-36, 38, 40-44, 46, 53 ----- 11, 16, 37, 45

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

& document member of the same patent family

Date of the actual completion of the international search

12 NOVEMBER 1999

Date of mailing of the international search report

25 JAN 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MICHAEL PAK

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/19902

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 23-31, 39, 47-52, 54-68
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Please See Extra Sheet.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/19902

BOX I. OBSERVATIONS WHERE CLAIMS WERE FOUND UNSEARCHABLE

2. Where no meaningful search could be carried out, specifically:

claims 23-31 are dependent on claim 21 which is not directed to the isolated polypeptide but to an isolated polynucleotide. Claim 39 is dependent on claim 31 which is not directed to the vector. Claims 47-52, 54, and 56 are directed to method of claim 38 but claim 38 is a vector. Claims 57-60 are directed amino acid sequences of claims 24-27, but claims 24-27 are dependent on claim 21 which are not directed to isolated polypeptide. Claims 55 and 61 does not clearly define whether the invention is directed to a computer system or a method and claim 63 is directed to claim 61 which is unsearchable. Claims 62 and 64 are dependent on a method of claim 60 but claim 60 is directed to a computer readable substrate and not a method. Claims 65-68 are dependent on claims 24-27 which are unsearchable because the claims 24-27 are dependent on claim 21 which are directed to isolated nucleic acid but not polypeptides.